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ABSTRACT 
 
ASHLEY MARIE LAKNER. Hepatic stellate cell transdifferentiation: profibrogenic 
effectors.  (Under direction of DR. LAURA W. SCHRUM) 
 
Hepatic fibrosis is a significant cause of morbidity and mortality worldwide and 
can be described as exacerbated wound-healing marked by excessive deposition of 
extracellular matrix components, predominantly type I collagen. Chronic injury 
stimulates accumulation of scar matrix synthesized by hepatic stellate cells (HSCs) 
resulting in distortion of normal liver architecture, disruption of blood flow and organ 
dysfunction.  In a normal healthy liver, HSCs are found in the quiescent state functioning 
to store vitamin A in the form of retinyl esters, regulate sinusoidal microcirculation, and 
maintain normal basement membrane conditions. Following exposure to fibrogenic 
stimuli, HSCs transdifferentiate to activated myofibroblast-like cells marked by increased 
proliferative and hypercontractile properties.  
Currently there are no FDA-approved treatments for hepatic fibrosis. Outside of 
surgical resection, orthotopic transplantation is an option for certain disease states; 
however, the current list of patients in need of transplant far exceeds the annual donor 
rate.  As HSCs are considered the primary effector cells of fibrosis, targeting various 
points of transdifferentiation and resolution to impede disease development/progression 
is of therapeutic interest. The process of HSC transdifferentiation is classically divided 
into initiation and perpetuation phases, each characterized by unique cellular events.  
Examination of genetic programming in early HSC transdifferentiation revealed 
coordinate changes in gene expression by components of JAK/STAT signaling. Chemical 
inhibition of this signaling pathway blocked HSC activation morphologically and through 
interruption of genetic reprogramming denoted by significantly decreased pro-fibrotic 
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gene expression. Post-transcriptional regulation of HSC transdifferentiation (initiation 
and perpetuation phases) is controlled, in part, by changes in global microRNA (miR) 
expression patterns. Specifically, miR 19b was significantly decreased in activated 
compared to quiescent HSCs. Overexpression of miR 19b in culture-activated HSCs 
significantly decreased pro-fibrotic transforming growth factor beta (TGF signaling by 
direct inhibition of TGFRII and subsequent decreases in collagen expression and 
markers of HSC activation. miR 19b expression was also significantly decreased in 
rodent models of fibrosis and in liver tissue from fibrotic patients, indicating miR 19b as 
a novel biomarker and possible therapeutic. Finally, examination of transdifferentiation 
resolution has indicated involvement of HSC apoptosis. However, newly 
transdifferentiated stellate cells display increased resistance to apoptotic stimuli. 
Aquaporins (AQP) are known regulators of programmed cell death in mediation of the 
apoptotic volume decrease necessary for downstream caspase and nuclease activation. 
Analyses showed AQP expression was significantly decreased in activated compared to 
quiescent HSCs. Quiescent HSCs expressing multiple AQP homologs responded to 
osmotic challenge, an effect abrogated by functional inhibition of AQPs. Similarly, 
quiescent HSCs were significantly more responsive to apoptotic stimulation, which was 
also abrogated by AQP inhibition. In vitro studies were confirmed in vivo utilizing liver 
tissue from a mild-fibrotic animal model. Dual fluorescent immunohistochemistry 
showed strong colocalization of aquaporins with quiescent, but not activated stellate 
cells.  
HSC transdifferentiation is highly complex with multiple pro-fibrotic signaling 
networks conferring phenotype-specific genetic reprogramming observed in hepatic 
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fibrosis. These studies provide insight into novel factors controlling initiation, 
perpetuation and resolution stages of HSC transdifferentiation as well as new avenues to 
be explored for therapeutic intervention.  
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CHAPTER 1: INTRODUCTION 
 
Hepatic fibrosis 
Hepatic fibrosis is a significant cause of morbidity and mortality and can be 
described as an exacerbated wound-healing response marked by excessive deposition of 
extracellular matrix (ECM) components, predominantly type I collagen.  Accumulation 
of ECM in the subendothelial space of Disse initiates a deleterious chain of events 
beginning with damage to the hepatocytes. Alterations in liver architecture are deemed 
transient and reversible during acute injury, whereas accumulation of scar tissue in 
chronic injury diminishes possibility of reversion [1-2]. Sustained hepatic insult can stem 
from a wide array of sources, including, but not limited to, viral hepatitis B/C infection, 
chronic alcohol consumption, and inborn errors in drug/xenobiotic metabolism. 
Geographic distribution of fibrosis is expansive; viral and parasitic infections stimulate 
disease development in the Eastern hemisphere, whereas chronic alcohol consumption is 
the major underlying cause in the US and Western Europe [3]. Left untreated, chronic 
injury can progress from early stages of mild inflammation and steatosis to a fibrotic and 
ultimately cirrhotic liver (end-stage liver disease), categorized by distortion of liver 
parenchyma and blood flow accompanied by organ failure. Additional health 
complications arising from the fibrotic disease state correlate with increased morbidity 
and mortality, and include portal hypertension, general metabolic impairments, ascites 
and encephalopathy [4].  
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Interestingly, while previous leading causes of death in the US have decreased in 
past decades (lung cancer, heart disease; American Cancer Society Statistics 2011), there 
is an increased burden of chronic liver disease reflecting the nation’s struggle with 
obesity, an emerging risk factor, and increased prevalence of hepatitis C-mediated 
fibrosis/cirrhosis [3]. This health burden confers additional disease risk, with a high 
percentage of chronic liver disease patients developing hepatocellular carcinoma (HCC), 
which is the fastest rising neoplasm incidence in the US and Western Europe [5].  
In progression from chronic injury to a fibrotic state (Figure 1.1), there are 
numerous changes in liver architecture. Hepatocytes lose microvilli and cellular polarity 
and undergo apoptosis/necrosis. The sinusoidal endothelial cell population lose their 
fenestrae causing capillarization of the sinusoids. Resident macrophages become 
activated and begin to secrete cytokines and chemokines. Lymphocytes will also infiltrate 
the injured tissue and evoke a heightened inflammatory response. Lastly, but of highest 
importance, is activation of the non-parenchymal hepatic stellate cell population [6-8]. 
Hepatic fibrosis is initiated by increased secretion and deposition of ECM proteins, 
primarily type I collagen, by the hepatic stellate cell (HSC) and hepatic myofibroblast 
pools. Comparable to normal ECM conditions, type I and III collagens are abundant, but 
injurious conditions contribute to the rise in type I over type III collagen [9-10]. 
Accompanying increased collagen deposition is decreased fiber degradation resulting 
from suppression of matrix metalloproteinase (MMP) activity and increased expression 
of tissue inhibitor of metalloproteinases (TIMPs). MMPs are subdivided into five 
categories: interstitial collagenases, gelatinases, stromelysins, membrane-type 
collagenases, and a metalloelastase (MMP-12). MMP1 is the predominant interstitial 
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collagenase in humans, while MMP8 and 13 serve identical function in rodents [11-12]. 
A variety of inflammatory cytokines and growth factors stimulate expression of MMP13, 
which is synthesized by both parenchymal and non-parenchymal liver cells. The 
imbalance in fibrinolysis and fibrinogenesis is also regulated by TIMP expression. TIMPs 
1, 2, 3 and 4 inhibit target MMPs by directly binding to catalytic domains. In addition to 
regulation of MMP expression, TIMP 1 indirectly inhibits HSC apoptosis [13]. Attempts 
to tilt the delicate balance of MMPs and TIMPs has been examined as a therapeutic 
approach. Overexpression of MMP8 via adenovirus abrogated carbon tetrachloride 
(CCl4) and bile duct-ligation (BDL) models of hepatic fibrosis in rats [13-14].  
Fibrotic scarring is inevitable in the presence of high ECM turnover, with a close 
topographical relationship between inflamed areas of the liver and those that develop 
fibrosis. A wide range of cytokines and soluble signals are implicated as fibrogenic 
mediators, including transforming growth factor beta (TGF) through its regulation of 
collagen, TIMPs and MMPs. Histological patterning of scar matrix are consistent in 
patients with cirrhosis regardless of etiology; however, initial location of inflammation 
and scarring in earlier disease states are stimulus specific.    
Despite recent advances in uncovering cellular and molecular events governing 
fibrotic wound-healing, no drug has been FDA-approved as an effective anti-fibrotic 
agent, underscoring the need for novel therapeutic approaches. In the lack of clear 
clinical progress, the organ itself aids in sustaining life and function of the fibrotic 
patient, as immense regenerative capacity of the liver, specifically hepatocytes, lends to 
slow disease progression. Although etiologies of chronic liver disease are variable, 
fibrosis remains the underlying commonality and thus of high interest in treatment of 
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chronic liver disease. While recent studies have turned focus to additional sources of 
circulating fibrocytes within the liver as fibrogenic mediators, the majority of research to 
date has been placed on understanding contributions made by stellate cells, which have 
long been considered the main effector cells of hepatic fibrosis [2, 13-15].  
Hepatic stellate cells 
HSCs once referred to as Ito cells, are lipid-rich cells found within the 
perisinusoidal space of Disse along the basolateral surface of hepatocytes with long 
dendritic-like processes encapsulating neighboring sinusoidal endothelial cells (Figure 
1.1). Vitamin A is sequestered within the liver (50-80% of the body’s stores), and 
resident HSCs store approximately 90% of total hepatic vitamin A. While principal 
cellular functions include storage of retinyl esters and subsequent secretion of retinol into 
portal blood flow when required, these cells also regulate hepatic microcirculation. HSCs 
are responsive to both vasoconstrictors and vasodilators, including endothelin-1 and nitric 
oxide, emphasizing the role of the cell as a liver-specific pericyte [16].  
Traditionally considered of mesenchymal origin, numerous studies have also 
demonstrated expression of both neural and neuroendocrine markers in HSCs, and more 
recently an epithelial-mesenchymal transition (EMT) process has been proposed as a 
possible source of stellate cells, further complicating the true origin [17-18]. As HSCs 
expresses both neuronal (nestin, glial fibrillary acidic protein (GFAP) and p75 
neurotrophin receptor) and mesenchymal markers (vimentin), the neural crest has been 
suggested as the point of origin [16, 19] . However, studies analyzing genetic lineage of 
these cells in drosophila failed to support this hypothesis, instead pointing to a mesoderm 
origin. It is well-established that mesoderm-derived progenitor cells give rise to both 
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adipocytes and neural cells, both of which express HSC markers. Of recent note, the 
septum transversum mesenchyme is a plausible origin, as mesenchymal cells in the 
septum transversum are locked into place by hepatoblasts and endothelial cells during 
development [20]. This hypothesis has been validated in a mouse model in which cell 
lineage analysis was performed using ROSA26 reporter mice with cre-recombinase 
driven by mesoderm specific gene (mesoderm posterior-1, MesP1) promoter [21-22].  
Stellate cells, named for their star-like morphology, comprise a mere 1.4% of total 
liver volume with approximately 4-6 HSCs : 100 hepatocytes. Under normal 
physiological conditions the HSC resides in a quiescent lipid-rich state (Figure 1.2), 
serving functions described previously. However, following hepatic injury, 
microenvironment-derived signals (primarily increased cytokine levels) stimulate 
activation of HSCs, wherein they transdifferentiate from a quiescent vitamin A storing 
cell to a myofibroblast-like cell (Figure 1.2). Myofibroblasts mediate the process of 
wound-healing in several solid organs. Not normally found in healthy tissues, sources of 
trauma, inflammation and infection stimulate the generation of myofibroblasts through 
transdifferentiation of resident cells [15, 23].  
Hepatic stellate cell transdifferentiation 
The HSC transdifferentiation process is highly complex with a multitude of 
changes occurring in cellular morphology and patterns of gene expression (Figure 1.3). 
The quiescent phenotype possesses various adipogenic features tightly regulated by 
expression of peroxisome proliferator activated receptor gamma (PPAR), the master 
regulator of adipogenesis [16]. The phenotypic shift from an adipogenic genetic profile to 
the myofibroblast is mirrored in the process of adipocyte differentiation. Like adipocytes, 
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HSCs store high concentrations of triglycerides in addition to retinyl esters. Additionally, 
both quiescent HSCs and adipocytes express type IV collagen as opposed to activated 
HSCs and pre-adipocyte fibroblasts, respectively. Interestingly, cytokines which suppress 
adipocyte differentiation stimulate activation of the HSC [epidermal growth factor 
(EGF), transforming growth factor alpha (TGF), and interleukin-1IL-1)] [24-26].  
Once recognized by autofluorescence, retinyl esters, and expression of GFAP, 
newly activated HSCs are characterized by expression of cytoskeletal protein smooth 
muscle-alpha actin (SMA) [27]. Parallel activation of resident macrophages (Kupffer 
cells), infiltration of monocytes and damage to parenchymal cells spur initiation of HSC 
activation through release of soluble factors [19, 28]. Platelet-derived growth factor 
(PDGF) and TGF are secreted into the hepatic microenvironment and bind to HSC 
surface receptors promoting the activated genetic program of the cell, stimulating pro-
fibrotic intracellular signaling cascades. Concomitant with activation, increased 
proliferative and contractile properties are obtained promoting sustained HSC activation 
(Figure 1.3). Classically the process of HSC transdifferentiation has been subdivided into 
initiation and perpetuation phases, each categorized by unique cellular and molecular 
events [16]. 
During initiation of transdifferentiation (termed pre-inflammatory stage), changes 
in gene expression and cell phenotype prime the HSC to respond to paracrine signaling, 
predominantly from damaged hepatocytes and increased surrounding reactive oxygen 
species (ROS) [29-30]. Perpetuation of HSC activation involves both autocrine and 
paracrine signaling pathways which regulate retinoid loss, contractility, proliferation and 
general fibrogenic features of the activated phenotype. Classic initiation factors include 
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hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), interleukin-
6 (IL-6) and, most notably, TGF [16].
Increased circulation of these and other proinflammatory factors from injured 
hepatocytes triggers HSC activation.  Importantly, apoptotic fragments released by 
hepatocytes are received as fibrogenic signals by both HSCs and Kupffer cells. During 
this process cytochrome (CYP) P450 enzymes are synthesized which generate ROS and 
stimulate increased collagen expression. The parallel process of Kupffer cell activation 
contributes to stellate cell transdifferentiation through cytokine signaling, predominantly 
TGF[31-32]. Additionally, as a consequence of hepatic fibrogenesis, gut permeability 
facilitates increased circulating levels of lipopolysaccharide (LPS), which can trigger an 
immense inflammatory response simultaneously activating macrophages and HSCs [33]. 
It is well-established that cirrhotic patients exhibit increased LPS in systemic and portal 
blood tracts.  In addition to predominant cytokines initiating HSC and Kupffer cell 
activation [34], direct interaction of LPS and fibrotic signaling components (e.g. toll-like 
receptors, TLRs) further stimulates fibrotic gene expression and sustained HSC activation 
[35]. Like resident liver macrophages, human HSCs express TLR4 and are able to 
respond to LPS stimulation. TLR4 and co-receptors MD-2 and cluster of differentiation-
14 (CD-14) transmit immunogenic signals to induce activation of Nuclear Factor-kappaB 
(NF-B) and c-jun n-terminal kinase/activator protein-1 (JNK/AP-1) signaling pathways 
in activated HSCs [36-37]. Following LPS treatment, TLR4 activation up-regulates 
various chemokines including monocyte chemotactic protein-1 (MCP-1) and RANTES 
(regulated upon activated, normal T cell expressed and secreted)  and down-regulates 
expression of bone morphogenic protein (BMP) [37]. TGF signaling is also increased as 
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a consequence of active TLR4 [38]. Studies utilizing HSCs isolated from collagen 
promoter-driven GFP transgenic mice exhibited increased collagen promoter activity 
when stimulated with LPS, with synergistic effects observed when cells were pretreated 
with LPS followed by TGF[38]. HSCs also express TLR2, a receptor for gram positive 
bacterial cell wall components, and TLR9, which recognizes bacterial unmethylated 
cytosinephosphoguanine (CpG)-containing DNA and induces transdifferentiation of 
HSCs in the presence of denatured DNA from apoptotic hepatocytes [33]. Functional 
genomic scans of chronic HCV patients identified seven single nucleotide 
polymorphisms (SNPs) that may predict risk of developing cirrhosis, with TLR4 T3991 
SNP serving as the second most predictive [39]. Taken together, TLR signaling appears 
critical in activation of HSCs in the context of fibrosis.  
Following initial robust paracrine signaling, the perpetuation phase describes 
distinctive changes in cellular behavior dictated by a wide array of soluble factors that 
cause a net effect of full myofibroblast genetic reprogramming. Post-liver injury, HSCs 
and other myofibroblasts migrate to sites of tissue injury to participate in active wound 
repair through secretion of ECM components [40]. Connective tissue growth factor 
(CTGF) serves as a fibrogenic signal for HSCs, observed to stimulate progression of non-
alcoholic steatohepatitis (NASH) to fibrosis by increasing proliferation and chemotaxis 
[41]. HSCs are known to migrate towards several cytokine chemoattractants, among 
which PDGF is most prominent [42]. PDGF-stimulated HSC chemotaxis involves 
movement of the cell body towards the stimulus, concurrent spreading at the leading edge 
of the cell and retraction of the lagging edge. These processes are highly linked to myosin 
phosphorylation events and non-muscle myosin isoforms are reported to be involved in 
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stellate cell migration [43-44]. Expression of SMA is increased with HSC 
transdifferentiation which confers increased migratory and contractile properties. Portal 
hypertension is a major complication of fibrosis/cirrhosis characterized by increased 
vascular resistance resulting in dangerous elevations in portal pressure and tissue-specific 
hypoxia [45]. As noted previously, HSCs are responsive to vasomodulatory signals and in 
hepatic injury HSCs are capable of constricting single sinusoids, thereby impeding blow 
flow. Following acute injury, contractile properties of the HSC prevents toxic blood flow 
to the liver; however, chronic disease states are associated with a permanent contractile 
HSC phenotype, disadvantageous to organ function [46].  
Factors contributing to the perpetuation phase of activation all serve a common 
purpose to increase the myofibroblast-like nature of the cell (i.e. increasing proliferation, 
contractility, chemotaxis and fibrotic gene expression). Following adequate tissue repair, 
decreased inflammatory signals and withdrawal of the injurious stimulus, the next 
proposed stage in transdifferentiation is resolution [2, 47-48]. However, fate of a single 
HSC is unclear; some have speculated a reversion to quiescence while others indicate 
programmed cell death will clear cells from the newly repaired area [48-51]. Conversely, 
studies have also indicated activated cells become highly resistant to apoptotic signals, 
which in turn only perpetuates the fibrotic response through sustained HSC activation 
[52]. 
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Prominent signaling components and pathways in HSC transdifferentiation 
Hormone and neurotrophic signaling 
Past decades of research have illustrated key pathways regulating the process of 
HSC activation, including initiation and perpetuation phases. The intrinsic lipocyte nature 
of the HSC in coordination with the known role of adipokines in mediating non-alcoholic 
fatty liver disease (NAFLD) has drawn investigators to examine adipokine signaling 
pathways that may regulate HSC activation. Adipokines are classically derived from 
adipose tissue, but are produced by resident hepatic cells including the HSC. Leptin is 
known to promote HSC-mediated fibrogenesis and increase levels of TIMP1 through 
stimulation of the janus kinase (JAK) and signal transduction and activator of 
transcription (STAT) signaling pathway [53-55]. Leptin also induces HSC 
transdifferentiation through repression of PPARwhich regulates and maintains the 
quiescent program of the cell. In a positive feedback loop, increases in leptin hormone 
and leptin-mediated signaling are further increased following transdifferentiation as 
expression of leptin receptor (OB-R) is significantly up-regulated in activated HSCs [56-
57].  
Additional hormonal mediators contribute to hepatic fibrosis, including thyroid- 
enhanced HSC activation and disruptions to the hypothalamic pituitary gonadal axis 
resulting in altered levels of androgens and estrogens [58-59] . Recent studies from our 
laboratory have shown that adrogenization increases susceptibility to alcohol-induced 
liver damage and that estrogen replacement in adulthood appears protective. In addition 
to pituitary-derived signals, neurotrophic factor signaling, specifically opioids, promote 
HSC transdifferentiation (increased proliferation and collagen production) and have 
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recently been investigated for anti-fibrotic therapy through use of receptor-antagonists 
[60-61]. Our lab recently reported that Nalmefene, a derivative of the opioid receptor 
antagonist Naltrexone, exerts immunomodulatory activity and decreases HSC activation 
in vitro. Another morphinan derivative, JKB-119, lacking receptor antagonism, also 
decreased HSC activation and significantly decreased hepatic injury in an in vivo model 
of acute inflammation [62]. Following liver injury, neuroendocrine factors are up-
regulated, and activated HSCs transduce these signals via specific receptor expression, of 
which highly fibrotic cannabinoid (CB) signaling is of current research interest [63-65]. 
Endogenous HSC cannabinoid  2-AG increases CB1 receptor (CB1R) and subsequent 
pro-fibrotic target gene expression. Efforts to develop CB1R antagonists have been 
successful in pre-clinical animal models with treatments leading to decreased steatosis 
and inflammation [63]. Conversely, studies have shown CB2 receptor to possess anti-
fibrotic hepatoprotective properties [66]. In cirrhotic rats CB2 agonist treatment 
attenuated fibrosis and CB2 knockout mice exhibited delayed liver regeneration in a CCl4 
model of liver injury [65]. 
Wnt signaling 
Canonical Wnt signaling is also prominent in regulation of HSC 
transdifferentiation. The Wnt signaling network is comprised of secreted glycoproteins, 
Wnt family ligands, and both frizzled and low density lipoprotein receptor-related protein 
(LRP) families of receptors. The classical pathway involves -catenin stabilization and 
subsequent gene expression, notably those involved in cell cycle progression [67-68]. 
Specifically, Wnt ligands bind to frizzled receptors to induce and increase -catenin and 
up-regulate transcription of target genes. In the absence of ligand binding, the 
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axin/glycogen synthase complex-3/adenomatous polyposis coli (axin/GSK-3/APC) 
complex promotes proteolytic degradation of -catenin and interrupts intracellular 
signaling [69]. Wnt proteins Wnt10b and Wnt3a are expressed in activated HSCs and are 
known to suppress adipocyte differentiation via PPARand CCAAT-enhancer-binding 
protein (C/EBP inhibition. Forced expression of co-receptor antagonist Dikkopf-1 
initiates reduction in nuclear -catenin thereby restoring expression of PPAR and 
converting myofibroblasts to quiescent cells capable of lipid retention [69]. Already 
reported to promote differentiation of both skeletal and smooth muscle cells and inhibit 
differentiation of adipocytes, Necdin is a new contributor to this classical pathway. 
Necdin directly interacts with the Wnt10b promoter in activated HSCs inducing Wnt 
expression [70]. Site-directed mutagenesis of the promoter binding site abrogated necdin-
mediated Wnt expression. Interestingly, silencing of this protein not only inhibited 
Wnt10b expression, but also reduced methyl-CpG-binding protein 2 (MeCP2) and 
histone 3 lysine 2 (H3K2) methylation which prohibits reversion of the HSC phenotype 
[70].  
Growth factor signaling 
PDGF signaling is perhaps one of the most well-described cascades regulating 
HSC activation [15-16, 71]. The principal mitgogen for mesenchymal cells consists of a 
family of A, B, C and D polypeptides which promote cell migration, proliferation and 
survival by binding to cognate receptors, PDGFR and PDGFR. Following ligand-
receptor binding, dimerization of receptor subunits is observed and tyrosine residues 
within the intracellular domain are phosphorylated. This single event leads to activation 
of phosphatidylinositol 3-kinase-Akt ( PI3K-Akt) and Ras-mitogen activated protein 
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kinase (Ras-MAPK) pathways which regulate pro-fibrotic gene expression. Activation of 
Ras in turn activates serine threonine kinases of the Raf-family, which subsequently 
phosphorylate MAPKK/MAP kinase kinase (MEK 1/2) activating extracellular regulated 
kinases (ERK 1/2). Once activated ERK 1/2 translocates to the nucleus to act as a 
regulator of gene expression, including those genes involved in cell cycle progression, 
apoptosis resistance and ECM remodeling [43, 71-72]. Previously, PDGF has been 
viewed as a promising target for pharmacological inhibition. Tyrosine kinase inhibitory 
compounds, such as Sorafenib, have proved moderately effective in treatment of HCC, a 
disease with underlying fibrosis, and may elicit similar effects in rodent models of strict 
hepatic fibrosis [73]. During perpetuation, canonical Akt signaling is stimulated by 
PDGF, leptin and other soluble factors. Parallel to Akt, JNK is activated by PDGF and 
additional factors upstream of MAPK affecting growth and cell survival signals. 
Inhibition of JNK in mice resulted in diminished fibrogenesis indicating that it too may 
serve as a potential target [40, 42].  
Signals propagated by EGF and TGF also stimulate the proliferative phenotype 
of the HSC, and again, via autocrine signaling, those same HSC-secreted growth factors 
are necessary to facilitate paracrine hepatocyte proliferation required during liver 
regeneration [55, 74-75]. Responsiveness to growth factors, of which only a select few 
have been described, initiates remodeling of the inflammatory milieu predominated by 
fibrillar collagens. A positive feedback loop is also established at this stage of disease 
wherein additional matrix-bound growth factors, notably TGF, are released as a 
byproduct of increased matrix stiffness and protease activity [32]. HSCs are not only an 
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important source of growth factors, but also of hepatic cytokines, underscoring the 
importance of autocrine control of HSC activation. 
Cytokine and chemokine signaling 
HSCs secrete and respond to pro-fibrotic cytokine signals, complicating our 
understanding of regulatory networks in a classical sense. Specifically, continual wound-
healing perpetuated by HSC activation is associated with increased IL-6 
expression/signaling as a byproduct of hepatocyte injury. Circulating IL-6 through 
binding of specific IL-6 receptors subsequently recruits two molecules of glycoprotein 
130 (gp130) to initiate the signaling cascade in the HSC [23, 76]. Classically, signal 
transduction is carried out by JAK2/STAT3; however, IL-6 may also propagate signals 
through parallel growth factor cascades. IL-6-ligand binding results in up-regulation of 
the acute phase response during immunogenic reaction to hepatic injury and perpetuation 
of HSC activation [76]. Inflammatory responses within the liver are also modulated by 
chemokine signaling pathways. Several chemokines and chemokine receptors are 
secreted and expressed by the HSC [77]. Recent work has identified specific chemokine 
receptors (CCR), CCR1 and CCR5, as fibrogenic factors as they generally promote 
migration of the HSC and subsequently enhance fibrosis by increasing inflammation [78]. 
Induced by NF-κB signaling, CCR5 stimulates HSC migration and proliferation, and 
CCR5 deficient mice are associated with markedly reduced hepatic fibrogenesis in both 
CCl4 and BDL models of hepatic fibrosis. Conversely, chemokines can be anti-fibrotic. 
CXCR3 knockout animals were shown to have a prominent pro-fibrotic phenotype, 
further substantiating the need for a deeper understanding of the chemokine impact on 
fibrotic disease progression and possible reversion [79].  
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Persistent inflammatory signaling is a critical component preceding and 
corresponding to levels of hepatic fibrogenesis. Activated HSCs secrete and respond to 
inflammatory cytokines and through expression of specific adhesion molecules (e.g. 
inter-cellular adhesion molecule-1, ICAM-1), interact directly with populations of 
immune cells [80]. Amplification of fibrotic signals is produced by an intact positive 
feedback loop wherein activated HSCs stimulate inflammatory responses from 
immunogenic cells, which in turn secrete cytokine signals that are recognized and 
interpreted by the HSC [81]. However, certain classes of immune cells, specifically 
natural killer cells, act independent of the positive feedback loop and maintain anti-
fibrotic properties as they kill activated HSCs through production of interferon gamma 
(IFN-) [82]. Several ongoing studies are examining the key interplay between HSCs and 
resident and infiltrating immune cells in fibrosis development and progression [83].  
In the hepatic microenvironment, TGFβ signaling regulates cellular wound-
healing responses including ECM production, growth and apoptosis. TGF is widely 
acknowledged as the most potent fibrogenic cytokine regulating HSC-mediated fibrosis 
(Figure 1.4) [84-85]. TGFalong with 35 structurally related proteins comprise the 
TGF superfamily, which includes three isotypes of the cytokine (1, 2, 3).  
Intracellular cleavage of pro-TGF produces latency-associated peptide (LAP) and 
mature TGFβ (C-terminal fraction) together forming a biologically inactive small latent 
complex. The secreted large latent complex is then formed when the small complex is 
paired with a latent TGF binding protein [85-86]. While not directly synthesized by 
intact hepatocytes, necrotic hepatocytes along with activated Kupffer cells and infiltrating 
immune cells, are sources of secreted large latent complex TGFβ [32, 85].  Matrix 
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fixation of the large latent complex is a pre-requisite for activation of the cytokine by 
proteases. Upon activation, TGFβ binds to the heteromeric receptor complex containing 
TGFβ type I (TGFβRI) and II (TGFβRII) receptors. Both autocrine and paracrine 
signaling propagates through the SMAD family of transcriptional activators. In the 
presence of TGFβ ligand, receptor-activated SMADs (R-SMADs), SMAD 2 and 3, are 
phosphorylated directly by TGFβRI kinase. Following phosphorylation, R-SMADs bind 
to common mediator SMAD4 and translocate to the nucleus to induce pro-fibrotic gene 
expression [32]. TGF plays a central role in mediating cellular crosstalk between 
inflammatory and collagen producing cells. Following liver injury, blood and tissue 
TGFβ levels are elevated stimulating the fibrotic response as both Kupffer and 
hepatocytes release the cytokine into the inflammatory milieu, inducing differentiation of 
neighboring cells. TGFβ signal transduction plays a critical role in establishment of the 
myofibroblast phenotype, as it directly up-regulates hallmarks of activation (SMA and 
collagen), propelling the disease state forward. Sustained TGF signaling increases 
matrix synthesis and HSC proliferation, marking the perpetuation phase of 
transdifferentiation (Figure 1.4) [15, 87].  
Multiple points of intervention within TGFβ signaling have been targeted to 
ameliorate and/or reverse fibrosis. Previous studies have shown that antioxidant S-
adenosyl-L-methionine (SAMe) exerts hepatoprotective effects. In a two-hit model of 
fibrosis, animals treated with SAMe displayed decreased TGF and SMAD3 mRNA 
corresponding to significantly decreased fibrosis [88]. Recently, in vitro studies have 
shown that SAMe significantly decreases type I collagen in activated HSCs, a mechanism 
mediated by increased polyubiquitination [89]. Overexpression of negative regulator 
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SMAD7 or inhibition of TGF receptors (soluble receptor and knock-out models) 
decreased hallmarks of HSC activation, particularly type I collagen and SMA, 
dramatically blunting chronic wound-healing [84, 90]. Anti-fibrotic potential of 
adenoviral vectors expressing truncated TGFRII significantly reduced as well as 
reversed dimethylnitrosamine (DMN)-induced fibrosis in several studies [85]. In vitro 
and in vivo (BDL) experiments demonstrated antisense mRNA and monoclonal 
antibodies against TGFRII abrogated TGF signaling and HSC activation accompanied 
by additional tumor suppressive effects, [91-93] emphasizing the importance of this 
signaling cascade in the foundation of and perpetuation of HSC-mediated hepatic 
fibrosis.   
While the aforementioned classical pro-fibrotic signaling pathways are more 
elucidated than newly emerging pathways (Wnt, leptin, cannabinoid), further 
experimentation is still required to fully understand the exact mechanisms by which these 
pathways are governed and potential mechanisms of crosstalk in transdifferentiation of 
the HSC.  
Transcriptional regulation of HSC transdifferentiation 
Changes in gene expression are required for HSC transdifferentiation to occur, as 
several signaling cascades become suppressed or activated during this critical transition 
period [94]. Mechanisms of gene regulation are complex and include a wide array of 
factors extending beyond traditional transcription factors (activators and repressors). In 
recent years epigenetic regulation of HSC activation has been uncovered providing new 
areas of translational research. Transition from a quiescent to activated stellate cell is 
accompanied by modulation of hundreds of genes. The shear plasticity of the HSC 
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facilitates this change and promotes cellular responsiveness to a variety of external cues, 
including inflammatory mediators and circulating fibrotic molecules. Several types of 
transcription factors have been described in detail for their roles in regulating 
transdifferentiation. 
HSCs express several basic helix-loop-helix transcriptional regulators, including 
MyoD, sterol regulatory element binding protein-1C (SREBP-1C), c-myb and c-Myc. 
Specifically, expression of c-myb is induced with HSC activation both in vitro and in 
vivo [95]. Studies have demonstrated interaction of c-myb with the SMA promoter 
leading to heightened protein expression. Additional studies in rat HSCs transduced with 
a c-myb antisense gene displayed diminished expression of not only SMA, but also type 
I collagen and TGF accompanied by decreased cell proliferation [96].  
The family CCAAT-enhancer-binding protein C/EBP family of transcription 
factors are also well noted in HSC literature as determinants of collagen expression [95, 
97-98]. While actions of the beta isoform appear to involve regulation of collagen 
expression by binding to a TGF responsive element in the presence of hydrogen 
peroxide (ethanol metabolite), opposite effects are seen with isoform . Expression of 
C/EBP is decreased in HSC transdifferentiation with forced expression in activated 
HSCs proving inhibitory to proliferative and fibrogenic signals, with additional in vivo 
studies pointing towards a role as a negative regulator of ECM production [97]. 
Well known Kruppel-like transcription factors (KLFs) bind to GC-rich and related 
CACCC boxes found in regulatory regions of pro-fibrotic genes, notably collagens. 
Stellate cells express several KLFs, including KLF6 and KLF10 [95, 99].  Like KLFs, 
highly related zinc-finger specificity protein 1 (Sp1) enhances procollagen gene 
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transcription via promoter binding. Additional crosstalk with SMAD3, transducer of 
classical TGF signaling, facilitates enhanced collagen promoter activity by Sp1 [100-
102]. KLF6 is dramatically induced during the early phase of HSC activation which 
coincides with increased suppression of the quiescent program. KLF6 stimulates 
transcription of collagen and TGF along with cognate receptors TGFRI and TGFRII 
[103-104].  
TGF achieves pro-fibrotic signaling action via HSC activation. After the 
signaling cascade has been triggered, phosphorylation of SMAD2/3 on specific serine 
residues occurs inducing R-SMADs to complex with Co-SMAD4. SMAD dimers then 
translocate to the nucleus to drive downstream target gene expression. SMAD7 serves as 
an inhibitory SMAD via interactions with cell surface receptors (via ubiquitination, or 
inactivation by deposhophorylation) [86]. HSCs express several SMAD transcriptional 
regulators, with in vitro data indicating expression of SMAD2 during initiation phases of 
activation, whereas SMAD3 is only detected in fully transdifferentiated cells [105]. In the 
setting of fibrosis, expression of the negative regulator SMAD7 is silenced which 
alleviates suppression of fibrotic signaling derived from the SMAD2/3/4 complex. In a 
rodent model of CCl4-induced liver fibrosis utilizing SMAD3 knockouts, suppression of 
procollagen gene expression and HSC proliferation were observed [106]. Additional 
studies by Dooley et al. have shown attenuation of fibrosis in vivo via forced 
overexpression of SMAD7 (adenoviral delivery) results in inhibition of R-SMADs and 
marked down-regulation of type I collagen and SMA expression [107]. Crosstalk 
between TGF and additional transduction pathways, including ERK1/2 and BMP, 
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occurs via SMADs further affirming the powerful properties of these transcriptional 
regulators [42].  
Human HSCs also express high levels of pregnane X receptor (PXR), which 
functions as a strict liver and intestine xenobiotic receptor activated by steroids and 
antibiotics [108]. Activation of  PXR, through a series of molecular events, leads to up-
regulation of CYP3A, facilitating metabolism of ~60% of prescription drugs. PXR 
maintains a regulatory role in lipid homeostasis through inhibitory actions to bile and 
metabolic signaling pathways [109]. Rifampicin antibiotic treatment targets PXR and 
results in inhibition of TGF and Wnt signaling pathways, attenuating fibrosis with long-
term treatment reducing proliferative capacity and activation of the HSC [108]. In 
contrast to the human condition, rodent HSCs do not express this particular receptor, as 
knockout mice were unresponsive to PXR activator pregnenolone-16alpha-carbonitrile 
[110].  
To compliment the retinoid storage capacity of quiescent HSCs, expression of 
both retinoid x receptor (RXR) and retinoic acid receptor (RAR) transcriptional 
regulators is observed. Following ligand binding and nuclear translocation, both factors 
bind to respective response elements to stimulate target gene transcription [111]. 
However, studies examining the role of these receptors in HSCs have been conflicting. 
While Milliano and Luxon demonstrated RAR subtypes were down-regulated upon 
culture-activation , others have shown RAR expression to be increased in the activated 
phenotype indicative of retinoid responsiveness [112]. All-trans-retinoic acid (ATRA) 
and 9-cis retinoic acid are ligands for RAR and RXR, respectively. Interestingly, while 
ATRA suppresses collagen expression without affecting proliferation, binding of 9-cis-
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RA suppressed both type I collagen synthesis and HSC proliferation [113]. Studies 
employing agonists to further elucidate protective effects of these transcription factors 
have been successful in vivo [114], with RXR transfection along with vitamin A 
administration attenuating the fibrotic response in mice.  
As briefly mentioned previously, quiescent HSCs do express transcription factors 
such as C/EBP and SREBP-1C, which along with liver X-receptor alpha (LXR-) and 
PPAR, regulate transdifferentiation of adipocytes [115]. All aforementioned factors are 
silenced during HSC activation and forced expression of both PPAR and SREBP-1C has 
been shown to reverse cells to the quiescent phenotype denoted by restored vitamin A 
and lipid storage capacity. PPARs are key regulators of fat metabolism and lipid 
retention, and all isoforms () are expressed in the HSC [116-117]. PPAR has 
received the most attention in the past two decades for its multifunctional role in 
adipocyte differentiation and transcriptional co-factor role in the dimerization of RXR 
[118]. Forced expression of the down-regulated nuclear receptor in activated HSCs 
stimulates partial reversion of the fibrogenic phenotype, marked by decreased type I 
collagen, inhibition of TGF signaling and subsequent re-expression of additional 
adipogenic transcription factors [116, 119]. Recent studies on the role of natural 
antioxidant curcumin as a fibrotic treatment attributed its protective effects to re-
expression of PPARand abrogation of inhibitory SMAD-PPAR promoter site binding 
[120-122]. The intricate role of PPAR in reversal of HSC activation has been studied in 
depth, demonstrating both natural and synthetic ligands for PPAR are able to suppress 
activation. Additionally, elegant studies by Mann et al. revealed a novel epigenetic 
mechanism by which PPAR expression is lost during HSC activation, and through both 
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in vitro and in vivo manipulation studies, restoration of PPAR and reversion of 
fibrogeneis was achieved [123]. The interplay between this master regulator of HSC 
transdifferentiation and other nuclear receptors, notably RXR and RAR, hold clinical 
promise as combination ligand treatment in culture-activated HSCs demonstrated a 
synergistic anti-fibrotic effect [95].  
NF-κB is as a master regulator of immune/inflammatory signaling pathways. 
Hepatic functions of NF-κB also include regulation of wound-healing in fibrosis. NF-κB 
is composed of 5 subunits, which hetero or homo-dimerize to form NF-κB and exert 
transcriptional influence by binding to distinct consensus sequences. Studies utilizing p50 
subunit knockout mice showed increased susceptibility to inflammation and fibrosis 
[124]. Following stimulation from various factors, including tumor necrosis factor-alpha 
(TNF- and LPS, IκB is phosphorylated by IκB kinase (IKK) on specific serine 
residues resulting in proteosome-mediated degradation of IκB. Removal of the inhibitor 
enables NF-κB to translocate to the nucleus and regulate transcription of target genes. 
NF-κB proteins are not restricted to one phenotype of the HSC; however, levels of 
transcriptionally active NF-κB are markedly increased post-activation. Proinflammatory 
genes IL-6, IL-8 and ICAM-1, require NF-κB for adequate expression in the activated 
HSC. NF-κB activation also produces anti-apoptotic signals; however stimulation of 
activated human HSCs with NF-κB inhibitors results in apoptosis [125-126]. Mann and 
colleagues have examined the mechanism by which NF-κB activation is essentially 
reprogrammed in the activated HSC [123]. Constant suppression of IB expression is 
observed post-HSC activation, which creates a paradox as NF-κB is transcriptionally 
active. The suppression has been attributed to a transcriptional repressor, CBF1, which is 
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induced during culture-activation prohibiting binding site access [123]. Additional 
properties of the DNA itself lend to repression, as methylation patterns recruit additional 
repressor molecules including methyl-CpG binding proteins and other epigenetic factors.  
Post-transcriptional regulation of HSC transdifferentiation 
Coordinate changes in gene transcription and simultaneous transcriptional 
repression occur during transition of quiescent to activated HSCs. For transdifferentiation 
to occur, it appears the quiescent genetic program must be suppressed, namely through 
silencing of PPAR, for activation of the myofibroblast program to begin [127-129]. 
Recently, studies have provided evidence for epigenetic regulation of HSC 
transdifferentiation [127, 129]. Alterations in HSC phenotype/gene expression arise 
during development, transdifferentiation and disease; however, these variations are not 
associated with changes to the underlying DNA sequence and are thus termed epigenetic 
[130]. Epigenetic regulation through methylation of DNA has been well described. This 
process occurs through addition of a methyl group to the 5’ position of cytosine residues 
in the CpG dinucleotide. Site-specific DNA methylation induces repression of gene 
expression, whereas unmethylated CpG sites correspond to genes that are constitutively 
expressed [130-131].  
In recent years focus of epigenetic research has shifted to include a broader range 
of  epigenetic mechanisms, with a concentration on modifications to chromatin structure. 
The unit of chromatin structure consists of 146 base pairs of DNA wrapped around an 
octamer of histones (H) containing two copies of H2A, H2B, H3, and H4. Higher-order 
chromatin is essential for functional organization of chromosomes as well as epigenetic 
gene regulation. Histone modifications have been identified as important epigenetic 
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mechanisms that influence chromatin structure. Modifications include, but are not limited 
to, methylation, acetylation and phosphorylation. Distinct modifications of histone tails 
regulate transcriptional “on” or “off” states and influence condensation state of chromatin 
and thus accessibility of transcription factors [132-133]. Post-translational modification 
of the histone N-termini, especially in the case of H3 and H4, have been well described in 
drosophila and more recently in higher-order vertebrates. Several groups have identified 
key lysine (K) residues on histone tails that once “marked” with modifications can then 
be interpreted by transcriptional complexes to give rise to specific phenotypes. Histone 
H3 when methylated at K9 or K27 conventionally leads to transcriptional repression, 
whereas methylation at K14 or K36 leads to transcriptional activation [130-131, 133-
135]. Histone marks that initiate repression are applied by different enzymes and 
complexes, including polycomb group proteins. 
A recent publication by Mann et al. examined the role of epigenetics during HSC 
transdifferentiation [123, 128]. Treatment of HSCs with a global DNA methylation 
inhibitor (5-aza-2-deoxycytidine) prevented quiescent HSCs from transdifferentiating 
into myofibroblast-like cells [123]. Further examination of transdifferentiation markers 
revealed a significant increase in both IκBα and PPARγ expression. Additionally, MeCP2 
was directly implicated in this process. MeCP2 has been shown to promote repressed 
chromatin structure and was only detected in the activated/myofibroblast-like form of the 
HSC. However, MeCP2 knockdown by RNA interference does not alleviate gene 
repression completely, indicating involvement of other mechanisms [136]. For MeCP2 
and several other methyl-CpG-binding proteins to contribute to repression, they must first 
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be recruited to the target gene and studies have shown this process is mediated by 
polycomb group proteins [137-139].   
CBF1 and MeCP2 contribute to methylation of CpG islands during stellate cell 
transdifferentiation [95, 123]. Levels of both factors are low in quiescent HSCs, 
contributing to heightened expression of IBα and inhibition of pro-fibrotic NF-κB 
activity. When expression of CBF1 and MeCP2 are increased, NF-κB is disinhibited 
promoting sustained HSC activation. Additional studies by this group have expanded our 
knowledge of this regulatory network, wherein PPAR is the target of epigenetic 
silencing by MeCP2. The transcriptional silencing is a product of a series of molecular 
events in which a specific microRNA (miR 132) is markedly reduced as a result of HSC 
activation resulting in overexpression of MeCP2, which binds to the PPAR promoter 
region to displace RNA polymerase-II. H3K9 methylation as a marker of transcriptional 
repression is observed at the 5’end of the target transcript [128]. In concert with MeCP2 
is enhancer of zeste homolog 2 (EZH2), a constituent of the polycomb repressive 
complex, which induces chromatin modifications necessary for sustained repression 
[128]. Treatment of quiescent HSCs with an EZH2 inhibitor prevented activation in vitro. 
These seminal studies provide the first clear link between microRNAs, epigenetic 
machinery and vital transcripts in HSC transdifferentiation. 
Post-transcriptional regulation of gene expression involves numerous 
modifications to the mRNA, including alterations at both 5’ and 3’ ends in addition to 
splicing of  transcripts. The 3’ untranslated regions (UTR) of mRNAs contain key 
stability elements subject to various regulatory proteins as well as miR binding sites. 
miRs are small non-coding RNAs which regulate gene expression through perfect 
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complementarity of the miR to the target sequence, inducing mRNA instability and 
subsequent endonucleolytic cleavage or alternate 5’ modifications [140]. Imperfect base 
pairing with the 3’ UTR of target mRNAs results in gene translation inhibition [141]. 
Research focusing on miR modes of action has primarily examined interactions with the 
3’ UTR of target genes; however, recent studies have expanded our knowledge, 
demonstrating  miRs can interact with the 5’ UTR as well as with DNA methylation 
machinery and affect chromatin status [142]. Since their discovery in 1993, miRs have 
been described in all multicellular organisms and are associated with a breadth of 
biological functions including proliferation, cellular differentiation, immunity as well as 
tissue remodeling and various human disease states, notably cancer [143]. Although 
much remains to be learned, miRs have already been shown to influence expression of 
many mRNAs and proteins important in liver homeostasis, health and disease.  
Commonalities of miR expression can be seen among fibrotic disorders of 
different organ systems, including both cardiac and renal fibrosis, with an overarching 
effect of the miR 29 family in regulation of cellular differentiation  and in translation of 
ECM [144]. Additionally, miRs involved with translation of pro-fibrotic TGF/SMAD 
signaling are shared amongst pathologies. Roderburg et al. examined miR expression 
profiles in a CCl4 rodent model of hepatic fibrosis [145] and microarray analyses 
revealed 31 differentially expressed miRs, 10 of which were overexpressed in fibrotic 
tissue, including miRs 125-p, 199b, 221, and 302c. Marked down-regulation was 
observed in a pool of 21 miRs; specifically, miR 29 family members were significantly 
reduced. Additional experiments in an alternate model of fibrosis (BDL) confirmed miRs 
29b/c were significantly reduced compared to sham controls. Down-regulation of miRs 
 27
29a/b/c was also observed in explanted liver samples with patients denoted by a Desmet 
fibrosis score of 2-4. Interestingly, low plasma levels of miR 29a correlated with 
advanced stage liver fibrosis in human patients. The hypothesis that low miR levels in 
tissue correlate with low miR in the circulating plasma is in opposition to recent 
hypotheses that an inverse correlation between tissue and plasma miR concentrations 
exists as a byproduct of vesicle-mediated miR release [146].  Hepatic fibrosis is 
influenced by several epigenetic factors controlling the wound-healing response. Recent 
studies by Mann et al. showed that miR 132 is significantly decreased in fibrotic livers as 
demonstrated in two different models (BDL, CCl4), and this down-regulation affected 
HSC activation [128]. Collectively, these studies emphasize that during development of 
fibrosis there are important changes in miR expression which regulate wound-healing 
transcripts; however, effects exerted by miRs appear to act in concert with other 
epigenetic factors to direct disease progression.  
Recently, studies examined miR expression in the HSC (Figure 1.5) as a possible 
avenue to affect fibrogenesis development and progression. Specifically, miRs 150, 187, 
194 and 207 were shown to be significantly down-regulated in HSCs isolated from BDL 
animals compared to sham controls, while let 7 family members were significantly up-
regulated [147]. Overexpression of miRs 150 and 194 in human HSCs (LX-2) resulted in 
proliferation inhibition as well as decreases in type I collagen and (SMA), hallmarks of 
HSC activation.  Specific action of these two miRs includes inhibition of c-myb and Ras-
related C3 botulinum toxin substrate-1 (Rac-1), which both contribute to development 
and progression of fibrosis.  Additional studies examined differential expression in 
quiescent (day 2) and activated (day 14) rat HSCs showing 12 up-regulated and 9 down-
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regulated miRs, of which 15b, 16, 122, 138, 140 and 143 were validated [148-149]. Gene 
ontology revealed specific linkages between the miR 15/16 family and anti-apoptotic 
pathways important in HSC activation.  Administration of miR mimics induced B-cell 
lymphoma-2 (bcl-2) inhibition and subsequent apoptosis in activated stellate cells, an 
important aspect of potential therapeutic targeting. Additional studies by Guo et al. 
further demonstrated that lentiviral delivery of miR 16 greatly reduced cyclin D1 levels 
in addition to inhibiting proliferation and increasing apoptosis in activated HSCs [149]. 
More recent studies by Ogawa et al. showed that TGF1 or IFN- stimulation validated 
in silico analyses of miR-pro-collagen [col 1(I)] mRNA binding sites [150].  miRs 29b, 
143 and 218 demonstrated the highest degree of homology to the col 1(I) 3’UTR and 
were further analyzed. miR 29b directly bound to the 3’UTR was effective at suppressing 
type I collagen at both mRNA and protein levels. Potential anti-fibrotic benefit to miR 
29b was also validated in vivo using a murine CCl4 model of injury.  In vitro studies 
conducted by Roderburg et al. also showed overexpression of miR 29b in murine HSCs 
resulted in decreased collagen expression and that both LPS and NF-κB are involved in 
the down-regulation of this miR [145]. Improved understanding of the regulation of HSC 
activation by miRs will undoubtedly advance our knowledge of many liver etiologies.  
miRs are processed from precursor molecules into pre-miRs within the nucleus. 
Once exported to the cytoplasm, the hairpin is cleaved by Dicer and strand selection 
occurs producing a mature miR available to associate with the RNA-induced silencing 
complex (RISC) [151]. Seminal studies have demonstrated miR biogenesis and 
processing are directly controlled by constituents in the TGF pathway. Several miRs are 
post-transcriptionally induced by TGF and nuclear accumulation of R-SMAD proteins 
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promotes Drosha-mediated miR processing [152-153]. In addition to HSC-mediated 
actions, increased levels of TGF observed in fibrosis may affect disease pathology by 
affecting global miR biogenesis/expression.   
Fibrosis resolution  
Death of hepatocytes and non-parenchymal cells is a central feature of chronic 
liver disease despite variation in etiology. The liver performs numerous critical processes, 
ranging from metabolism to detoxification, which requires profuse amounts of energy 
reliant on aerobic strategies [3, 154]. Increased cell death and impaired tissue 
regeneration are commonalities in most hepatic diseases, but unlike other organs the liver 
is capable of regenerating from extreme cell loss through stimulation of cell cycle 
machinery and increased hepatocyte proliferation. For example, post-70% hepatectomy 
(rat), a time frame of one week or less is sufficient for the liver to regenerate to original 
mass [155]. However, regenerative capabilities can be stunted if cellular loss exceeds an 
unknown threshold. Unfortunately, in hepatic fibrosis derived from chronic ethanol 
abuse, rate of hepatocyte cell death exceeds regeneration time frames, allowing a window 
for HSCs to displace functional hepatocytes with synthesized scar matrix, compromising 
hepatic function culminating in organ failure [10, 156-157].  
While cell death is undesirable in the parenchyma, resolution of hepatic fibrosis 
has been achieved through induction of apoptosis in collagen producing stellate cells. 
HSC-associated apoptotic mechanisms of cell death are set apart from the highly 
prominent necrotic death of hepatocytes, wherein cellular components are essentially 
spilled into the extracellular space [49, 158]. Necrosis is commonly the result of 
metabolic perturbations including drug-induced liver injury and hepatotoxicity, whereas 
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apoptotic, or programmed cell death, is a highly ordered cascade of intracellular events, 
initiated by the apoptotic volume decrease (AVD), designed to minimize inflammatory 
responses commonly provoked during necrosis.  
During the AVD intracellular K+ levels decrease from 140mM to < 35mM, a pre-
requisite for downstream caspase and nuclease activation [159-160]. These, and other, 
changes in intracellular solute concentrations result in the creation of a sustained osmotic 
gradient and net water loss from the cell resulting in the cell “shrinkage” characteristic of 
all apoptotic cells [159, 161]. Previous studies demonstrate water movement during the 
AVD occurs via aquaporins (AQPs) [159-160, 162]; a family of transmembrane proteins 
ubiquitously expressed in plant and animal cells [163]. Additionally, inhibition of AQP-
dependent water movement during the AVD significantly slows the progression of 
apoptosis [160-161, 164]. Of the known 13 mammalian homologs [165-166], seven have 
been identified in the liver and play important roles in hepatobiliary physiology and 
patho-physiology, including cell death in hepatic tumor cells [162, 167]. 
Classically, following an apoptotic stimulus, the intrinsic (mitochondrial-
mediated) pathway of apoptosis is activated. External cues induce proapoptotic proteins 
of the bcl2 family (bax, bad, bim) and subsequently activate release of cytochrome C 
from mitochondria. Cytosolic cytochrome C couples with Apaf-1 (Apoptotic protease 
activating factor-1) to form the apoptosome, where the first initiator caspase (caspase-9) 
is cleaved. In contrast to intrinsic pathways, extrinsic apoptosis is mediated by binding of 
an extracellular ligand to a specific transmembrane receptor, forming the death-inducing 
signaling complex (DISC). Upon activation, initiator caspase-8 is also capable of 
cleaving caspases 3 and 7. Once execution by either caspase-8 or caspase-9 has been 
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achieved, apoptotic signaling culminates in cleavage of poly (ADP-ribose) polymerase 
(PARP) and highly distinctive nuclear events including chromatin condensation and 
DNA degradation with characteristic cytoplasmic blebbing. Apoptotic cells eventually 
fragment into apoptotic bodies and are phagocytized by neighboring cells (primarily by 
macrophages). Various stimuli initiate cellular apoptosis, including death receptor ligands 
(Fas and TNF-), growth factor deprivation and DNA damage [168]. Studies by Iredale 
and colleagues showed that in coordination with resolution of biliary fibrosis there was a 
significant decrease in activated HSCs denoted by decreased SMA 
immunohistochemical staining which coincided with an increased rate of apoptosis [9-
10].  
Recovery from chronic liver injury is characterized by increased apoptosis of 
HSCs, subsequent reductions in TIMP levels and increased degradation of fibrous scar 
matrix [16]. Regression of hepatic fibrosis has been reported in various rodent models of 
the disease. Specific induction of apoptosis in HSCs by TNF-related apoptosis-inducing 
ligand (TRAIL) was achieved in studies by Tamir et al., proposing a unique therapeutic 
target for hepatic fibrosis, as hepatocytes do not express the necessary TRAIL-R2/DR5 
receptor to progress through TRAIL-mediated apoptosis [169].  
While additional factors (including doxorubicin and etoposide) typically induce 
apoptosis in parenchymal cells, previous studies have shown that as a byproduct of 
activation, newly transdifferentiated stellate cells display increased resistance to apoptotic 
stimuli [52]. While activated HSCs do have the capacity to undergo apoptosis via specific 
targeting by pro-apoptotic agents or spontaneously, increased resistance to proapoptotic 
signals is observed. Studies have utilized several pharmacological agents to induced 
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apoptosis in the HSC. Gliotoxin (GTx), perhaps best characterized of these agents, is a 
fungal metabolite inhibitory to NF-κB-mediated cell survival. GTx treatment induces 
apoptosis in both human (LX-2) and primary rat HSCs, and reduced fibrotic injury in a 
CCl4 model [170-173]. Interestingly, culture-activated cells compared to freshly isolated 
HSCs display heighted bcl-2 expression, which could contribute to increased resistance to 
apoptosis [52].  
Disease detection and therapeutic strategies 
Chronic alcohol consumption, hemeochromatosis, NASH and severe viral 
infection can all lead to development of hepatic fibrosis. Of particular importance is the 
relationship between fibrosis and obesity. With obesity on the rise in the Western world, 
there is a parallel rise in NASH , which can progress to fibrosis and in some cases HCC 
with underlying cirrhosis [174].  Only in recent history has hepatic fibrosis been 
considered reversible. Removal of the etiological agent has induced reversion of the 
fibrotic condition in patients with hepatitis C, biliary fibrosis and autoimmune hepatitis. 
Experimental rodent models of hepatic fibrosis have corroborated these results and 
highlighted the withdrawal of proinflammatory and fibrogenic cytokines, namely TGF, 
for decreased ECM production and reduced numbers of activated HSCs [3].  
Critical progress has been made in elucidating signaling pathways, transcriptional 
regulators and epigenetic factors governing HSC-mediated fibrogenesis. Obstacles are 
still present prohibiting translation of basic science advances to the clinical setting; 
however, with the constant influx of new technologies and collaborative efforts, several 
challenges of progress should be met in the near future.  
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One such challenge to advancement is the need for accurate disease 
detection/biomarkers of fibrosis disease progression. Liver biopsy, while standard care of 
practice, only provides a small window (~1/50,000th of the organ) into the status of  liver 
tissue and underlying cellular microenvironment [3]. Additionally, due to the invasive 
nature of the procedure, a limited number of biopsies are permitted for any one individual 
patient. To this end, miR expression signatures have been implicated as novel potential 
indicators of stage and activity of disease in human patients, with recent studies showing 
strong correlations and predictive success between miR expression and disease outcome 
[175-178].  
Currently there are no FDA-approved treatments for hepatic fibrosis. Outside of 
surgical resection, full organ transplantation is an option for certain disease states; 
however, the current list of patients in need of transplant far exceeds the annual donor 
rate [174].  While there are no drug regimes targeting transcription factors specifically in 
the HSC, targeting of PPARas well as NF-κB has been successful in other disease states 
[179]. A class of drugs known as glitazones, currently in use for the treatment of type 2 
diabetes mellitus, stimulate insulin production via activation of quiescence regulator 
PPAR; however, side-effects of this particular class of drug treatment remain substantial 
as liver enzymes are elevated in fibrotic patients which may counter-act benefits of 
glitazone therapy. Additionally, drugs targeting human PXR activation may also prove 
therapeutically beneficial. Rifampicin is currently prescribed for biliary cirrhosis to limit 
pruritus, but has also been shown in clinical trials to reduce serum levels of alkaline 
phosphatase (marker of liver damage) [15].  
 34
Drug targeting has been limited with regards to dominant pro-fibrotic TGF 
signaling; however, studies in rodents have demonstrated manipulation of this pathway 
holds therapeutic potential. Specifically, attenuation of fibrogenesis was achieved 
through TGFsurface receptor and SMAD inhibition [84]. However, drug/therapy 
development targeting TGF signaling must also consider the paradoxical role of the 
cytokine in fibrosis, as TGF possesses anti-inflammatory properties and is also an 
important regulator of hepatocyte proliferation necessary for organ regeneration.  
As is always the case, clinical applications of new discoveries, such as existence 
and manifold roles of miRs in liver physiology and pathophysiology, lag behind 
laboratory-based discoveries summarized above.  Thus, currently, profiles of miRs in 
various liver diseases and corresponding alterations in expression patterns as prognostic 
indicators or for categorization of liver diseases have not been introduced to routine 
clinical practice.  A likely application will be the profiling of miR expression in hepatic 
tumors as an aid to prognosis and, perhaps, to help guide therapeutic decisions and 
choices of therapies.   
 It seems that therapy directed at influencing the hepatic levels of selected miRs 
such as miR 122, already shown to play an important role in affecting levels of serum 
cholesterol and levels of the HCV, both in cell culture [180-181] and chimpanzee models 
[182], will find a place in clinical therapeutics.  Indeed, phase II clinical studies of locked 
nucleic acids that down-regulate miR 122 expression are already in progress, and results 
of these are awaited with high interest.  Similarly, therapeutic alteration of miR 196 [183] 
and, in future, other miRs seem likely also to be pursued.  However, there are high costs 
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and lengthy duration usually needed for approvals of all new drugs.  Then, too, the 
unwanted side-effects of such treatments may limit their clinical application. [184]  
 Therapies are desperately needed to bridge the time lapse between patients 
awaiting and receiving donor organs, as current options are limited to liver cell 
transplantation which has only shown mild clinical success due to donor hepatocyte 
insufficiency and high cell death following transplantation [3]. It is clear after review of 
the current literature that in HSC-mediated fibrogenesis there is not a common cure-all 
for the disease. Certain treatments designed to inhibit signals that promote deleterious 
HSC activation adversely effect signaling networks critical to neighboring cells (e.g., 
hepatocyte growth factor inhibition). Therefore, in efforts to identify putative therapeutic 
targets to ameliorate HSC activation and hepatic fibrosis, one must diversify 
experimental models, incorporating physiological relevant components of the hepatic 
microenvironment. Additionally, new advances will likely be derived from systems of 
combination therapy. The field of carcinogenesis and cancer therapy has validated 
benefits of combination therapies as synergistic effects are observed giving rise to 
increased disease suppression and increased recovery rates [185-187]. When examining 
inhibitory actions against HSC activation to attenuate fibrosis ,the value of combination 
therapies and possible synergistic effects on cellular and molecular components must also 
be examined. While promise of gene therapy has been lacking in past years, recent 
studies are providing new vector systems that may improve safety and efficacy of anti-
fibrotic drug delivery directly to the HSC. Previous studies have shown antibody-targeted 
delivery (SMA) of GTx to be an effective antifibrogenic therapy [188]. Studies have 
also observed that neo-glycoprotein mannose-6-phosphate-albumin (M6PHSA) 
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accumulates efficiently in HSCs during liver fibrosis and when coupled to anti-fibrotic 
pentoxifylline (PTX) reduced collagen expression significantly in activated HSCs [189]. 
Studies are still needed to uncover unique gene expression profiles and cellular qualities 
during varying stages of activation for cell-specific targeting to be successful in the 
absence of parenchymal or systemic effects.  
The process of HSC transdifferention is highly complex with breadth and depth 
existing in pro-fibrotic signaling networks conferring genetic reprogramming. Therefore, 
this dissertation examined multiple points of HSC transdifferentiation to uncover novel 
targets for therapeutic intervention and/or combination therapy. Specifically this 
dissertation examined the following: 
1. Transcriptional regulation of the initiation phase of transdifferentiation 
through JAK2/STAT3. The central aim of this study was to investigate an 
array of 21 genes over 10 consecutive days in culture to identify candidate 
signaling pathways and genes which peak early in expression to initiate and 
commit the HSC to activation/transdifferentiation.  
2. Post-transcriptional regulation of TGF-mediated HSC transdifferentiation by 
miR 19b. We hypothesized that decreased miR 19b in activated HSCs 
directly promotes fibrogenesis through regulation of TGFRII.  
3. AQP-mediated apoptotic mechanisms regulating resolution stages of 
transdifferentiation. We hypothesized that decreased AQP expression in the 
activated HSC confers increased resistance to apoptosis.  
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Figure 1.1 Intrahepatic effects of liver injury. The liver is comprised of four major cell 
types, hepatocytes, sinusoidal endothelial cells, Kupffer cells and HSCs. In a setting 
devoid of injury, plates of hepatocytes and non-parenchymal cells in hexagonal 
arrangement radiate from the central vein forming functional subunits of the liver. Injury 
to the parenchyma results in activation and recruitment of inflammatory cells. Release of 
soluble factors including TGF activate HSCs and stimulate wound-healing. Deposition 
of fibrillar scar matrix and other sinusoidal events observed in liver injury are depicted 
above. (Figure from Iredale, Pharmacological Research, 2008) [190] 
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Figure 1.2 Representative light micrographs of HSCs. The quiescent phenotype is 
depicted in panel A, while fully activated myofibroblast-like cells appear in panel B. In 
the normal liver HSCs reside in the quiescent state, spindle-like in shape with 
cytoplasmic projections, but exposure to hepatic insult stimulates transdifferentiation of 
the cell producing an activated HSC denoted by stretched polygon morphology and loss 
of autofluorescent properties.  
A B 
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Figure 1.3 Transdifferentiation of HSCs. HSCs reside in the space of Disse in the 
quiescent phenotype functioning to store vitamin A, regulating normal basement 
membrane conditions and hepatic microcirculation. Following exposure to a fibrogenic 
stimulus, HSCs transdifferentiate from quiescent lipid-rich cells to activated 
myofibroblasts devoid of retinoid droplets and marked by expression of SMA and a 
highly proliferative and contractile phenotype. Activated HSCs migrate to sites of injury 
where they produce and secrete scar matrix components to facilitate wound-healing. 
(Figure adapted with permission from Rippe, RA) 
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Figure 1.4 TGF signaling stimulates and perpetuates HSC transdifferentiation. 
Tissue and blood levels of TGFare elevated following injury. Increased paracrine 
signals derived from hepatocytes and Kupffer cells stimulate transdifferentiation of the 
HSC from a quiescent (blue cell) to activated (purple cell) phenotype increasing 
fibrogenesis. Autocrine signals perpetuate inflammatory signaling resulting in increased 
matrix deposition and wound-healing. (Figure adapted from Friedman, Nature Medicine, 
2007). [191] 
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Figure 1.5 miRs involved in HSC transdifferentiation. Functional manipulation 
studies utilizing mimics and/or antagomirs have demonstrated that the miRs depicted in 
the above schematic regulate key genes/functions in HSCs. Quiescent HSC: yellow 
circles represent cytoplasmic lipid droplets; activated HSC: purple lines indicate 
cytoskeletal protein SMA; green oval represents bcl-2; red fibrils represent collagen). 
Additional profiling studies have shown up-regulation of several miRs in both 
phenotypes, some of which are already associated with hepatic disease (boxes contain a 
small fraction of published miRs). (Figure from Lakner et al. World J. Gastro, 2011). 
[184]
 
 
 
 
 
CHAPTER 2: MATERIALS AND METHODS 
 
 
2.1 Chapter 3 materials and methods 
HSC isolation and culture 
Primary HSCs were isolated from male Sprague-Dawley retired breeder rats 
(>600g) (Charles River, Raleigh, NC). In situ liver perfusion using a pronase (Roche 
Molecular Biochemicals; Chicago, IL)/ type I collagenase (Sigma-Aldrich; St. Louis, 
MO) digestion was performed followed by Optiprep (Axis-Shield; Oslo, Norway) density 
gradient centrifugation. Cells were recovered at approximately 95% purity based on 
autofluorescence and washed with Gray’s Balanced Salt Solution (GBSS: 137 mmol/L 
NaCl, 2.7 mmol/L NaHCO3, 5.0 mmol/L KCl, 1.5 mmol/L CaCl2-2H2O, 1.0 mmol/L 
MgCl2-6H2O, 0.7 mmol/L Na2HPO4, 0.2 mmol/L KH2PO4, 0.3 mmol/L MgSO4-7H2O, 
5.5 mmol/L glucose, 25 mmol/L HEPES) and either used immediately (termed: freshly 
isolated, Q or quiescent) or cultured on plastic using Dulbecco’s Modified Eagles 
Medium (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (Atlanta 
Biologicals, Lawrenceville, GA), 2 mmol/L L-glutamine (Gibco), 100 units 
penicillin/mL, 0.1 mg/mL streptomycin, and 0.25 g/mL amphotericin B (Sigma-
Aldrich, St. Louis, MO) in 5% CO2 humidified atmosphere at 37
 °C. Growth media was 
changed every 2 days unless otherwise noted. All animal procedures were performed 
under the guidelines set by the University of North Carolina at Charlotte Institutional 
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Animal Care and Use Committee and are in accordance with those set by the National 
Institutes of Health.    
Treatment of HSCs 
HSCs were either harvested immediately (day Q or quiescent) or were grown in 
culture for the designated number of days (every 24 hours from the time of plating is 
considered 1 day). Cells were treated continually with 100 mol/L AG490, a JAK2 
inhibitor (CalBiochem, San Diego, CA). Media during treatments was changed every 24 
hours.  
Isolation of RNA and quantitative PCR  
Total RNA was isolated from HSCs using TRIzol reagent (Gibco-BRL, 
Gaithersburg, MD). RNA isolated from Q through day 3 was then cleaned using the 
RNEasy Clean-Up (Qiagen) following manufacturer’s recommendations. Total RNA was 
reverse-transcribed using Superscript II reverse transcriptase (Promega, Madison, WI) 
following manufacturer’s recommendations. qPCR was run at 94oC 15 s; 58oC 25 s; 72oC 
20 s, read 5s (Table 3.1). Reaction mixture consisted of 1 l each of cDNA, forward and 
reverse primers at 5 nmol/L, 2 l DEPC water, and 5 l of SYBR Green Master Mix 
(Qiagen). Primers listed in Table 3.1 were all designed for rat. cDNA concentration was 
used as a reference to normalize samples since the expression of housekeeping genes was 
modulated through days in culture. Data were reported as cross-point, the point at which 
the detectable level of SYBR green fluorescence was detected above the background. All 
experiments were performed a minimum of three times, as noted. 
 
 
 44
Microscopy 
For microscopic images, cells were visualized with transmission light microscopy 
at 200X magnification. A second exposure was taken under fluorescent light with a DAPI 
filter to image the fluorescent retinyl esters within the HSC using an Olympus IX71 
microscope (Olympus America, Inc.; Hamburg, Germany). The white light image was 
overlaid with the fluorescent image to produce the final image.  
Author contributions 
 Dr. Alyssa A. Gulledge was responsible for generation of data and study design 
with guidance from Dr. Laura W. Schrum. 
Data analysis 
Data are presented as mean ± SEM. One way repeated measures ANOVA was 
used for determination of statistical significance between the control and treatment 
groups using SigmaStat version 2.0. A p value of less than 0.05 was considered 
significant. AMADA 2.0.7 software was used to perform cluster analyses using 
Spearman correlation and average linkage [192].    
2.2 Chapter 4 materials and methods 
miRNA isolation, purification and microarray  
Total RNA was isolated from samples using Trizol Reagent (Invitrogen, Carlsbad, 
CA) per manufacturer’s instructions. The integrity of the RNA was verified by an Agilent 
2100 Bioanalyzer profile (Agilent Technologies Inc., Santa Clara, CA). The RNA was 
Poly (A) tailed and ligated to biotinylated signal molecules using the FlashTag™ Biotin 
RNA labeling Kit (Genisphere, LLC, Hatfield, PA). An Enzyme Linked Oligosorbent 
Assay (ELOSA) QC assay was performed to verify labeling prior to array hybridization. 
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Hybridization, washing, staining and scanning were performed using Affymetrix 
GeneChip® system instruments (Affymetrix, Santa Clara, CA). Affymetrix GeneChip® 
Operating Software (GCOS) version 1.4 was used to analyze microarray image data and 
to compute intensity values. Affymetrix .CEL files containing raw, probe-level signal 
intensities were analyzed using Partek Genomics Suite (Partek, St. Louis, MO). Robust 
multichip averaging (RMA) was used for background correction, quantile normalization 
and probeset summarization with median polish [193]. Statistical difference was 
calculated by two-way ANOVA analysis with false discovery rate (FDR). Partek miRNA 
workflow was used to access TargetScan target prediction database [194] to perform 
miRNA - mRNA target integration. 
Primary hepatic stellate cell isolation, culture and imaging 
Male Sprague Dawley rats ( > 500g) were purchased from Charles River 
Laboratories (Wilmington, MA) and housed in facilities approved by the National 
Institutes of Health. All surgical procedures were reviewed and approved by Carolinas 
Medical Center Institutional Animal Care and Use Committee. Primary rat HSCs were 
isolated by pronase/collagenase perfusion digestion followed by subsequent density 
gradient centrifugation as previously described [195]. Cell purity and viability were 
confirmed by autofluorescence and trypan blue staining, respectively. HSCs were 
maintained in Dulbecco’s modified Eagle medium supplemented with 10% fetal bovine 
serum (FBS), 100 U/ml penicillin and 100 g/ml streptomycin. Culture medium was 
replaced every 48 hours unless otherwise described and cells incubated at 37°C with 5% 
CO2. To document morphological changes, representative images were captured using an 
Olympus IX71 microscope (Olympus America Inc., Center Valley, PA). 
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Quantitative Real-Time polymerase chain reaction and immunoblotting 
For miRNA analysis, first-strand complementary DNA synthesis was performed 
using TaqMan® MicroRNA Reverse Transcription Kit primed with miR-specific primer 
(Applied Biosystems, Foster City, CA). Real-time quantitative RT-PCR (qRT-PCR) was 
performed using the TaqMan® MicroRNA Assays (Applied Biosystems), following the 
manufacturer’s recommendations, with an ABI Prism 7500 Sequence Detection System 
using  TaqMan® Universal Master Mix (Applied Biosystems).  Fold change values were 
calculated by comparative Ct analysis and normalized to 4.5S rRNA concentrations 
[196]. For mRNA analysis, total RNA was isolated from primary HSCs, and cDNAs 
were synthesized as previously described [94]. mRNA expression was measured by the 
CFX96 Real-Time PCR Detection System using 50 ng cDNA, gene-specific 
oligonucleotide primers (Supplementary Table 4.S1) and IQ SYBR Green Supermix 
(BIO RAD, Hercules, CA). The ddCt method was used to calculate mRNA expression 
levels as normalized to -actin [94]. Proteins were isolated and subject to SDS-PAGE 
electrophoresis and transferred to nitrocellulose membranes as previously described 
[195]. Bradford assays were used to measure protein concentration and Ponceau S 
staining verified equal protein loading. After blocking, membranes were incubated with 
primary antibodies (-actin and TGFRII, Santa Cruz Biotechnology, Inc, Santa Cruz, 
CA; MeCP2, Abcam, Cambridge, MA; Type I Collagen, Meridian Life Sciences, Saco, 
ME) overnight at 4°C followed by incubation with HRP-conjugated secondary 
antibodies. Chemiluminescence was used to visualize immunoreactivity as previously 
described.  
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Transient transfection  
Activated HSCs (day 6) were subject to transfection with mature miR 19b and 
negative control probes using Lipofectamine 2000 (Invitrogen; Carlsbad, CA)  according 
to manufacturers’ instructions. Briefly, cells were plated at a density of 1-4 x 105 cells/ml 
in standard culture medium following isolation. Cells were washed 3X with Opti-MEM I 
Reduced Medium prior to addition of transfection complexes. Lipofectamine-mimic 
complexes were incubated for 20 minutes and added to HSCs in Opti-MEM at final 
concentrations of 25, 50 and 75 nM. After 6 h, transfection medium was aspirated and 
replaced with standard culture medium supplemented with 5% FBS. Recombinant TGF 
(Sigma-Aldrich; St. Louis, MO) was added at a concentration of 5 ng/ml after the 6 h 
period. Dual luciferase vector (pEZX-MT01) containing the full length 3’UTR of 
TGFRII was purchased from GeneCopoeia, Inc (Rockville, MD). Following standard 
restriction digestion confirmation of control and TGF 3’UTR containing vectors, HSCs 
were co-transfected in 100 mm dishes with 4.8 g of reporter plasmids and mature miR 
19b or negative control (75 nM) using Lipofectamine 2000 as described above. 48 h post-
transfection culture medium was aspirated, protein was harvested and luciferase activity 
was analyzed using the GeneCopoeia Luc-Pair miR Luciferase Assay system. Firefly 
luciferase was normalized to Renilla luciferase activity and ratios normalized to total 
protein as determined by Bradford assay. 
Immunocytochemistry and in situ hybridization 
Prior to transfection culture-activated HSCs were seeded onto glass coverslips. 
Cells were transfected as described above and fixed with 4% paraformaldehyde and 
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stained with anti SMA antibody from Millipore (rabbit monoclonal). Slides were 
visualized using a Carl Zeiss confocal microscope (LSM 710) with 200X magnification. 
Liver tissues were obtained from following fibrotic models:  bile duct-ligation/sham 
[Schrum lab, unpublished data], ethanol/lipopolysaccharide [88]. Sections (6 m) were 
cut from all paraffin embedded tissues (RNase free). In situ hybridization was performed 
using mercury LNATM detection probes, 5’-DIG and 3’-DIG labeled miR 19b according 
to manufacturer’s instructions (Exiqon, Woburn, MA). 
Human tissue samples 
Human fibrotic (Metavir score of 3 or 4) liver biopsy samples (n=21) were 
obtained from the Liver-Biliary-Pancreatic Program Repository at Carolinas Medical 
Center (Charlotte, NC). Informed consent forms were signed by each patient from which 
samples were collected and approval from the Institutional Review Board was obtained. 
Normal controls (n=7) were obtained from the Liver Tissue Cell Distribution Center 
(LTCDS) specimen bank (Minneapolis, MN).  
Statistical analysis 
Data are presented as mean ± SE as determined from at least three independent 
experiments. Statistical analyses were performed using one way analysis of variance or 
student’s t-test where appropriate, with p values < 0.05 considered significant and 
denoted by *.  
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2.3 Chapter 5 materials and methods 
Animals 
Male Sprague-Dawley rats (Charles River; Raleigh, NC, 650-750g) were used in 
these studies. All experiments were approved by the Institutional Animal Care and Use 
Committee at UNCC. 
Materials  
Type IV collagenase, Dulbecco’s Modified Eagles Medium (DMEM), and HgCl2, 
were purchased from Sigma-Aldrich (St. Louis, MO). Gliotoxin (GTx) was purchased 
from BIOMOL International (Plymouth Meeting, PA). TRIzol reagent, Superscript III, 
Image-iT FX Signal Enhancer and ProLong Gold with DAPI were purchased from 
Invitrogen (Carlsbad, CA). Antigen Retrieval Citra Solution was purchased from 
BioGenex (San Ramon, CA). The Bradford assay was purchased from BioRad 
Laboratories (Hercules, CA). Antibodies against AQP 0, 1, 5, 8, and 9 were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA), and antibodies against AQP 11 and 12 
were purchased from FabGennix (Frisco, TX). The antibody against Poly (ADP-ribose) 
polymerase (PARP) was purchased from Abcam (Cambridge, MA). Antibodies against 
α-SMA, glial fibrillary acidic protein (GFAP), donkey anti-rabbit fluorescein and donkey 
anti-goat rhodamine were purchased from Millipore (Billerica, Massachusetts). The 
CaspACETM Assay System was purchased from Promega (Madison, WI). 
HSC isolation and culture 
Primary HSCs were isolated from male Sprague-Dawley rats  following in situ 
liver perfusion-pronase/type I collagenase digestion as previously reported [88]. Typical 
cell purity following isolation was  95%. Cells were either used immediately (quiescent; 
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dQ; 4 hours), or cultured on plastic using DMEM supplemented with 10% FBS, L-
glutamine (2 mM) and antibiotics for 14 days (activated; d14) as previously described 
[88]. Culturing HSCs on plastic is routinely used to mimic the in vivo activation process.  
Treatment of HSCs and morphological assessment  
Quiescent (4 hours) and activated (d14) HSCs were treated with GTx [0.15 or 1.5 
µM (final medium concentration), 20-90 minutes] or vehicle (DMSO) in the absence or 
presence of HgCl2 pre-treatment (100 µM; 15 minutes). Mercurials, including HgCl2, 
through steric hindrance prohibit AQP pore formation and thus inhibit water/solute 
movement [197]. At the end of the experimental period, cells were assessed for 
morphological changes and representative images captured using an Olympus IX71 
microscope (Olympus America, Inc., Center Valley, PA). Cell number was assessed by 
direct cell counts. Additionally, cell viability was determined by trypan blue exclusion 
assay.   
Reverse transcription PCR (RT-PCR) and RealTime PCR  
Total RNA was isolated from dQ and d14 HSCs using TRIzol, DNase treated and 
reverse transcribed with Superscript III according to the manufacturer’s directions. RT-
PCR was performed using primers specific against rat AQP homologs (Table 5.S1) for 
92oC 30s; 58oC 30s; 72oC 30s for 35 or 40 (AQP 0, 4, 5) cycles. Two sets of primers for 
each AQP homolog were utilized to confirm results. PCR products were visualized on 
ethidium bromide gels and sequences verified. All experiments were performed in 
triplicate. RealTime PCR was run at 94oC 15 s; 58oC 25 s; 72oC 20 s, read 5s. Reaction 
mixture consisted of 1 L each of cDNA, forward and reverse primers at 5 nmol/L, 2 l 
DEPC water, and 5 L of SYBR Green Master Mix (Qiagen).  Data were reported as 
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cross-point, the point at which the detectable level of SYBR green fluorescence was 
detected above the background.  
Cell lysate preparation and immunoblotting  
dQ and d14 HSCs were washed with PBS and whole-cell extracts prepared using 
ice-cold RIPA buffer [1% (v/v) NP-40, 0.5% (v/v) deoxycholate, 0.1% (w/v) SDS, 
0.5mM phenylmethylsulfonyl fluoride, 0.05 mM Na3VO4, 2 g/mL aprotinin in PBS] and 
sonicated. Total protein concentrations were determined and samples corrected to equal 
concentration prior to loading. Western blot analysis and detection were performed using 
antisera specific against the AQP homologs as previously described [162].  Primary 
antibodies were used at a dilution of 1:1000 (AQP 0, 1, 8 and 9), 1:500 (Cleaved PARP), 
or 1:250 (AQP 5 and 11) and incubated overnight at 4oC.  Secondary antibody (anti-goat-
HRP, anti-rabbit-HRP) was used at a dilution of 1:2000-1:5000 and incubated for 1 hour 
at room temperature. 
Osmotic challenge and cell swelling analysis  
Cell size was analyzed using a Becton Dickinson FACSCalibur (San Jose, CA) as 
previously reported [162]. Briefly, to measure basal (untreated) cell membrane water 
permeability, dQ and d14 HSCs were re-suspended in culture medium (106 cells/ml). 
Cells were then incubated at 37°C for 15 minutes and cell size analyzed by forward 
scatter. Cells were next subjected to osmotic challenge whereby culture medium 
osmolality was adjusted to 210 mOsM for 30 seconds. At the end of this period, cell size 
distribution was measured and histograms overlaid for comparison. In parallel 
experiments, dQ and d14 HSCs were pre-treated with HgCl2 (100 µM; 2 minutes), and 
cell size distribution was measured prior to and after osmotic challenge.  
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Caspase activity  
dQ HSCs (106 cells) were allowed to adhere in culture for 4 hours using DMEM 
supplemented with FBS [10% (v/v)] prior to treatment. In parallel d14 HSCs were seeded 
onto 6-well plates (106 cells) one day prior to treatment. Cells were either untreated or 
pre-treated with HgCl2 (100 µM; 15 minutes) and stimulated to undergo apoptosis by the 
addition of GTx, a fungal metabolite that induces apoptosis in human and rat HSCs in 
vitro and in vivo [170, 173] [GTx; 0.15 or 1.5 µM (final concentration)]. In a parallel 
series of studies the pan-caspase inhibitor Z-VAD-FMK (Z-VAD; 50µM) was added 
simultaneously to GTx-treated HSCs as a negative control. After 20, 45 or 60 minutes 
culture medium and adherent HSCs were harvested, pelleted by centrifugation (450 x g 
10 minutes; 4oC), and HSCs lysed by freeze-thaw. The lysates were then centrifuged 
(15000 x g 20 minutes; 4oC), and the supernatant collected and analysis performed using 
a CaspACETM Assay System according to the manufacturer’s instructions. Activity levels 
were normalized to protein concentration. 
Dual fluorescent immunohistochemistry 
 Liver tissue was obtained from an ethanol/LPS (ELPS) fibrotic animal model 
[88]. Four micron sections from formalin fixed paraffin embedded tissues were cut and 
deparaffinized with three changes of xylene (10 minutes), cleared with two changes of 
100% ethanol and rehydrated with two changes of 95% and 70% ethanol and water. 
Cross-linked proteins were exposed using heat-induced epitope retrieval solution. Slides 
were washed and incubated with signal enhancer to quench background fluorescence. 
PBS containing donkey serum was used to block slides for 20 minutes. Slides were then 
incubated with primary antibody cocktail and allowed to incubate overnight at 4oC (AQP 
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8 1:25/GFAP 1:500, AQP 8 1:25/SMA 1:200, AQP 9 1:50/GFAP 1:500, AQP 9 
1:50/SMA 1:200). Slides were washed with PBS then dark incubated with secondary 
antibody cocktail (rhodamine 1:400, fluorescein 1:400) for one hour. Slides were rinsed 
with PBS and coverslipped with ProLong Gold with DAPI and allowed to cure overnight. 
Fluorescent staining was visualized using the Olympus IX71. Images of AQPs 8, 9, 
GFAP and α-SMA were taken separately at identical exposures and color channels 
merged using Image-Pro software (Media Cybernetics, Inc., Bethesda, MD). 
Statistical analysis  
Data are presented as mean ± SEM. One way repeated measures ANOVA with 
Tukey’s post hoc test was used for determination of statistical significance between 
groups using SigmaStat version 2.0 (Ashburn, VA). A p <0.05 was considered 
significant. 
 
 
 
 
CHAPTER 3: DAILY GENETIC PROFILING INDICATES JAK/STAT SIGNALING 
PROMOTES EARLY HEPATIC STELLATE CELL TRANSDIFFERENTIATION 
 
 
 
Introduction 
Hepatic stellate cells (HSCs) play an important role in the development of liver 
fibrosis.  Following exposure to a fibrogenic stimulus (e.g. virus, toxins, alcohol), the 
quiescent HSC transdifferentiates into an activated myofibroblast-like cell.  During this 
process the HSC undergoes morphological changes (i.e. stellate cell to a stretched-
polygon morphology), becomes hypercontractile and increases expression of fibrillar 
collagens and cytokines [15].  Increased collagen deposition leads to accumulation of 
scar matrix, a major cause of liver dysfunction during hepatic fibrosis [23]. The 
transdifferentiation process, while very difficult to monitor in vivo [198], can be seen and 
studied in vitro. HSCs in vivo undergo transdifferentiation when exposed to an altered 
microenvironment (e.g. increased type I collagen deposition as seen in fibrosis). This 
process can be mimicked in vitro by culturing these cells on a plastic substrate. Several 
groups have performed microarray analyses on both in vitro and in vivo HSC activation 
[199-200]; however, little is known about the daily genetic alterations that occur. To 
understand this complex process, it is necessary to know the sequential activation of key 
genes, as well as the rise and fall of expression levels. Therefore, based on known gene 
expression profiles of the quiescent and activated HSC, several genes were selected to 
follow throughout the transdifferentiation process. 
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 HSCs are an important source of cytokines, and cytokine cross-talk is the main 
pattern of cellular communication in the injured liver.  Specifically, continual wound-
healing perpetuated by HSC transdifferentiation is associated with increased IL-6 
expression, an important cytokine involved in the acute phase response observed post-
liver injury [16].  IL-6 initially binds to specific receptor IL-6R (gp80) and subsequently 
two molecules of gp130 are recruited leading to activation of down-stream signaling. 
Classically, for induction of pro-inflammatory target genes, canonical JAK/STAT 
signaling is activated leading to increased inflammation as well as degradation of ECM 
[76]. Signaling pathways such as the MAP kinase (MAPK) pathway are also transduced 
with the activation of soluble IL-6R [201]. However, studies have shown that JAK/STAT 
signaling is the primary pathway for up-regulation of pro-inflammatory mediators/genes 
during acute phase response II, the body’s innate immune response provoked as a result 
of liver injury [201]. JAK/STAT downstream signaling affects expression of numerous 
genes including those involved in cellular proliferation and migration. Additionally, 
JAK/STAT signaling is associated with down-regulation of anti-apoptotic genes, 
including bcl-2 family proteins [202]. Stimulation of proliferative pathways (MAPK) and 
increased cellular differentiation by JAK/STAT signaling promotes the fibrotic response 
and leads to increased activation of HSCs [23]. Additionally, our lab has shown 
(unpublished data; Schrum lab) JAK/STAT signaling increases collagen expression at 
both mRNA and protein levels supporting that this pathway is critical in modulating 
fibrosis.  
To determine the daily genetic profile during normal transdifferentiation in HSCs, 
the expression of a mini-array of 21 genes (including members of the IL-6 JAK/STAT 
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signaling pathway) across 10 days in culture was examined.  Our results clearly 
demonstrate unique genetic profiles during different days of transdifferentiation and 
select days of activation showed similar patterns of gene expression.  Results of the 
genetic and day cluster analyses suggest responsiveness of the cell to different signals 
will depend upon the temporal state of transdifferentiation.  Inhibition of JAK/STAT 
signaling impeded the progression of HSC transdifferentiation as assessed 
morphologically and by gene expression.  Thus, our data indicate that JAK/STAT 
signaling may play a key role in the initiation of HSC transdifferentiation and that the 
changes in gene expression during a precise time period within the activation phase may 
determine the response of the HSC during this process. 
Results 
Gene expression profile time-course  
To generate a daily profile for gene expression, 21 genes were selected as 
representatives of cellular behavior exhibited by HSCs. They included standard 
housekeeping genes (-actin, G3PDH, HPRT), markers of quiescence (GFAP, PPAR), 
markers of activation (SMA, Desmin), matrix remodeling genes (col 1(I), col , 
MMP13), mitotic and migratory associated genes (CycD, FAK, RhoA, PDGFR), and pro-
fibrotic cytokines, including the IL-6 JAK/STAT signaling pathway (IL-6, IL6R, JAK2, 
SOCS3, STAT3, TGF, TGFR). Total RNA was harvested at day Q and days 1-10 at 
exact 24 hour intervals (n=4) and converted to cDNA for quantitative PCR analysis. 
These data were graphed as raw mRNA expression based on cycle number and 
subsequently normalized to total cDNA concentration. In order to examine relative 
fluctuations in gene expression, all genes were normalized to day Q (Figure 3.1A).  
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Since wide variations existed in mRNA expression of G3PDH, HPRT and -actin 
based on total cDNA content (Figure 3.1A), a housekeeping gene was not used for 
normalization. For example, when IL-6 was normalized to a housekeeping gene (G3PDH, 
-actin or HPRT), large variations in gene expression were observed (Figure 3.1B). 
Therefore, total cDNA concentration was used for normalization to quantitate daily 
changes in gene expression.  
Due to the extensive amount of data generated from the mini-array, AMADA 
software was used to detect significant relationships in gene expression patterns. Genes 
with similar expression patterns over 10 days of culture were clustered together (Figure 
3.2A). Genes incorporated in the same bracket have a more comparable expression 
pattern than those outside that bracket. The degree of correlation decreases with the 
distance between bifurcations [203]. Further examination identified that SMA and 
collagen 1(I) and 2(I)were similarly regulated, while FAK, TGFR and Desmin 
displayed a similar yet not identical regulation as they were positioned on adjacent 
brackets. Conversely, GFAP, IL-6, JAK2, MMP13 and SOCS3 had distinctly different 
expression patterns as they were separated by multiple bifurcations.  Additionally, 
PPAR demonstrated the least amount of relatedness to any other gene.  Interestingly, a 
majority of IL-6 signaling pathway constituents (IL-6, JAK2, SOCS3) were clustered 
together indicating a high degree of correlation in expression pattern, while STAT3 and 
IL-6R exhibited a divergent expression pattern from these three IL-6 signaling 
components.  
Clustering software was utilized to demonstrate which days of culture-activation 
were most closely linked based on gene expression profile (Figure 3.2B).  Day Q is 
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distinct from all other days in culture. Days 1, 2 and 3 were closely linked, with day 1 
having a more comparable gene expression profile to day 2 than day 3. Days 5 and 6 
were also well-coupled as were days 7-10; however, as in all hierarchal clustering 
dendrograms, ordering within the bracket is arbitrary and thus does not contribute to the 
relatedness. Day 4, like day Q, exhibited a distinct expression profile that did not directly 
correspond with other days in culture indicating these days may be important cellular 
transition points.  
Markers of gene expression  
After examining gene expression by mini-array, we further dissected distinct 
markers of quiescence (GFAP, PPAR; Figure 3.3A), markers of early activation 
(MMP13, IL-6; Figure 3.3B), markers of late activation (SMA, Desmin, col 1(I), col 
 Figure 3.3C), pro-fibrotic markers (TGF, TGFR, MMP13, PDGFR; Figure 
3.3D) and constituents of the IL-6 JAK/STAT signaling pathway (IL-6, IL6R, JAK2, 
SOCS3, STAT3; Figure 3.3E).  Classic quiescent markers were clustered closely and 
decreased steadily over days in culture (Figure 3.3A), while markers of early activation 
increased sharply on day 1 and fell to basal levels over time (Figure 3.3B).  Consistent 
with previous findings in our lab, we observed approximately a 103-fold induction in 
MMP13 mRNA and a 100-fold induction in IL-6 mRNA expression from day Q to day 1.  
Markers of HSC activation increased steadily for the first seven days of activation then 
plateaued (Figure 3.3C).  PDGFR, TGF and TGFR expression increased after day 2 
and remained constant (Figure 3.3D). Notably, five genes in the IL-6 JAK/STAT 
signaling pathway were coordinately regulated during early HSC transdifferentiation 
(Figure 3.3E). Although differences in gene expression magnitude existed, the 
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overarching pattern remained consistent. These data suggest the IL-6 JAK/STAT 
signaling pathway may be linked to regulation of HSC transdifferentiation which 
warrants further investigation. 
 JAK/STAT pathway in early HSC transdifferentiation  
Since gene expression analysis indicated early transient spikes in IL-6, JAK2 and 
STAT3 mRNAs (Figure 3.3E), contribution of this signaling pathway to the initiation of 
HSC transdifferentiation was examined.  A specific JAK2 inhibitor, AG490, was used to 
block JAK/STAT signaling within the cell to determine if inhibition of this pathway 
could alter changes seen in transdifferentiation. Cells were exposed continually to AG490 
over a five day period and assessed morphologically at days 1, 3 and 5.  Culture-activated 
HSCs lose retinyl esters and cytoplasmic processes, and proliferate vigorously.  As 
indicated by black arrows, cytoplasmic processes were only evident at day 1 in control 
cells (Figure 3.4) compared to day 3 and 5 which exhibited stretched-polygon 
morphology characteristic of the activated phenotype. However, HSCs treated with 
AG490 retained these cytoplasmic processes over five days in culture indicating an 
inhibition of the activated phenotype and suggesting the importance of the JAK/STAT 
signaling pathway in early HSC transdifferentiation.   
 AMADA software was again used to cluster days based on gene expression 
profiles of the AG490-treated cells (Figure 3.5).  Cluster analysis indicated that the 
expression profile of the HSCs treated with the inhibitor on days 1, 3 and 5 shared a high 
degree of relatedness to day Q as opposed to later days in culture.  Specific gene 
expression associated with HSC activation was also examined.  Inhibiting the JAK/STAT 
pathway with AG490 clearly showed a significant decrease in expression of markers of 
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activation (collagen, SMA, PDGFR and TGFR) thereby impeding early HSC activation 
(Figure 3.6).  Day 3 showed the most prominent reduction of gene expression compared 
to day 1 and day 5.  Even though significant decreases in gene expression were observed 
on day 5, a less dramatic effect was seen compared to day 3 suggesting JAK/STAT may 
be involved in early transdifferentiation and plays a lesser role during later stages.  
Discussion 
The process of HSC transdifferentiation is key in understanding and eventually 
ameliorating liver fibrosis. During the course of HSC transdifferentiation there are 
several genes/proteins that are altered in expression. Genes involved with lipid/vitamin A 
regulation [97, 115, 117], such as peroxisome proliferator activated receptor gamma 
(PPAR)[116, 204], are lost, while cytoskeletal genes are shifted, decreasing glial 
fibrillary acidic protein (GFAP) but increasing desmin and smooth muscle- actin (SMA) 
[205-208].  Manipulation of PPAR expression by adenoviral expression in activated 
cells leads to a reversal of the activated phenotype (flattened polygonal morphology with 
prominent actin stress fibers) to the quiescent phenotype (retracted cytoplasm and 
appearance of processes) [209].  These phenotypic changes are also correlated with 
decreased expression of HSC activation marker genes such as collagen and TGF[209].  
Extracellular matrix components change from normal basement matrix components, such 
as type IV collagen, to a fibrotic matrix, including type I collagen [210-212]. In all 
previous studies, quiescent HSCs or HSCs in early activation have been compared to 
activated cells. Although continuous changes throughout the transdifferentiation process 
have been observed, changes in gene expression/profiles have not been tracked in a daily 
manner defining which days show similar phenotype and which days serve as a 
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transition. While individual components of HSC phenotypes have been identified, there 
has been no concerted attempt to demonstrate the interplay of relevant genes as they 
coordinate the transition from a quiescent to a fully activated phenotype.  
 The initial stimulus of the transdifferentiation process has not been identified; 
however, several cytokines including TGF, TNF- and IL-6 have been implicated 
[213].  Several labs have previously used microarray analysis to examine differential 
expression of genes in HSCs [199, 214].  However, these studies examined two or three 
specific time points, rather than daily changes or gene relationships that could play a role 
in the initiation of transdifferentiation. In a study by DeMinicis et al., HSCs cultured for 
20 hours represented the quiescent phenotype and day 5 culture-activated cells were 
considered fully activated [199] and in another study, days 0, 4 and 7 were the selected 
populations [214].  Further, other studies examined cells at days 0 and 15 along with a 
third time point where cells were cultured until they had been passaged six or seven times 
[215]. The aforementioned studies are not consistent with days HSCs are considered to be 
quiescent (ranging from freshly isolated to day 1 or 2) or activated (ranging from days 5 
to 15 of culture-activation).  Varying degrees of quiescence and activation can lead to 
inconsistent results and misinterpreted data.  None of these studies followed the 
transdifferentiation process on a daily basis.   Therefore, these previous studies could not 
pinpoint transitions and steady-state profiles.  Additionally, because of the multitude of 
time points, data generated in these studies are not comparable to each other. Therefore, 
for the first time, our study analyzed an array of 21 genes over consecutive days in 
culture to identify candidate signaling pathways and genes which peak in expression to 
initiate and commit the HSC to activation/transdifferentiation.   
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 Using AMADA software, genotypic clustering was performed to profile genes 
that are modulated in quiescence, early and late activation, and pro-fibrotic conditions. 
This analysis demonstrated that day Q was clearly divergent from all other days during 
transdifferentiation, while days 1-3 were significantly different from days 5-10 (Figure 
3.2B).  Further, day 4 is genetically distinct from other days in culture, suggesting this 
may be the commitment point to the activated phenotype.  Although no dramatic changes 
in gene expression were seen at day 4, commitment to expression patterns was observed 
suggesting day 4 is a critical point of transition (Figure 3.3).   Additionally, components 
of IL-6 JAK/STAT signaling pathway appeared to be crucial in the first 72 hours of HSC 
transdifferentiation. 
Our results also demonstrated that blocking the JAK/STAT signaling pathway 
inhibited phenotypic changes seen during activation as indicated by retention of 
cytoplasmic projections (Figure 3.4) and significantly decreased pro-fibrotic gene 
expression (Figure 3.6).  JAK/STAT signaling can be transduced by numerous 
factors/ligands including IL-6, leptin and interferon gamma (IFN-) which are also 
associated with HSC activation [54, 213].   
IL-6 is up-regulated in liver disease, with positive effects on liver regeneration 
and protection from hepatotoxins. IL-6 is an important cytokine in the regulation of 
immune and acute phase responses during bacterial infections or damage [216]. It can be 
synthesized by a variety of liver cells, including Kupffer cells (KCs), hepatocytes [81] 
and HSCs [217-220], as well as infiltrating lymphocytes, monocytes/macrophages, 
endothelial cells, smooth muscle cells and fibroblasts [216, 221].  Conversely, IL-6 
signaling can also be detrimental. In the case of liver fibrosis, it is pro-fibrotic causing 
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perpetual type I collagen stimulation by the HSCs [216].  Thus, fibrogenic effects of 
autocrine and paracrine IL-6 signaling and the specific contribution of each on initiation 
of HSC activation and perpetuation warrants further investigation.  
The pro-fibrotic hormone, leptin, binds to OB-RL transducing its signal through 
the JAK/STAT complex.  Culture-activated but not quiescent HSCs express leptin [222] 
resulting in significant increases in 2(I) collagen mRNA [223] and suppression of 
PPAR[224].  Inhibition of JAK2 with AG490 impeded leptin signaling thereby 
ameliorating the fibrotic response [225].  In contrast IFN is considered to be anti-fibrotic 
and also signals through the JAK/STAT pathway. Pro-fibrotic cytokine TGF increases 
ECM deposition from activated HSCs contributing to disruption of liver architecture in 
fibrosis.  IFN- has been shown to abrogate the activation of TGF and diminish the 
excessive wound-healing response [226].  While it is clear that JAK/STAT signaling is 
important in the fibrotic response of HSCs, the specific ligand initiating 
trandifferentiation is yet to be elucidated.  Numerous studies have demonstrated that 
signaling through the MAP kinase (MAPK) pathway leads to increased HSC proliferation 
promoting the fibrotic response [23, 201].  However, JAK/STAT signaling is the primary 
pathway for up-regulation of pro-inflammatory mediators/genes during liver injury [201], 
and no studies to date have examined the significance of JAK/STAT signaling during 
early HSC transdifferentiation. 
We describe here that freshly isolated HSCs are distinct from all days of culture-
activation and that these cells should not be equated with or used interchangeably with 
early days in culture.  Based on our daily genetic profile assessment, the day of culture-
activation used could significantly impact studies examining different cellular processes 
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including transdifferentiation, proliferation, gene expression and migration of the HSCs.  
It would be interesting to determine if other fibrogenic stimuli such as alcohol or 
acetaldehyde could also initiate HSC activation through JAK/STAT, particularly given 
that commitment to the activated phenotype perpetuates the fibrotic response. Overall, 
these data demonstrate the daily changing genetic profile of the HSC results in 
differentiation into a unique phenotype rendering the cell sensitive to ligands which 
signal through JAK/STAT.  Since inhibition of the JAK/STAT signaling pathway 
impedes the progression of HSC transdifferentiation/activation, this may serve as a 
potential therapeutic target to inhibit or slow the development of liver fibrosis.        
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Table 3.1 Primers used in this study.  
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Figure 3.1 Gene expression profile time course.  (A)  Mini-array of 21 genes across 10 
days in culture as analyzed by RealTime PCR. Results are averages from three separate 
experiments. Quiescent time point was set to 1 for all genes.  (B)  Classic housekeeping 
markers (G3PDH, -actin and HPRT) fluctuated over days in culture-activation, thus 
they served as unreliable normalization markers.  
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Figure 3.2 Clustered genetic and day analyses.  (A)  The genes were grouped based on 
the degree of relatedness in their expression patterns over time using AMADA software. 
Distance relationships were calculated using Spearman rank correlation (D 0 - 2). The 
shorter the distance between two genes, the more similar the expression profile over days 
in culture.  (B) The clustering tree demonstrated which days in culture were most 
coordinately regulated. As expected, day Q branches alone, while culture-activated HSCs 
are more closely regulated.  Unexpectedly, day 4 also branched alone.  
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Figure 3.3 Gene expression markers during different stages of HSC activation. 
Markers of quiescence, early and late activation, fibrosis and the IL-6 signaling pathway 
(A-E respectively) were examined over ten days in culture. RealTime PCR was used to 
analyze gene expression. Fold induction was relative to the day Q expression levels. Data 
are presented as mean ± SEM.   
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Figure 3.4 Inhibition of JAK/STAT signaling pathway: morphological alterations. 
Culture-activated HSCs were treated continually with AG490 throughout a five day 
period and subsequently analyzed morphologically at days 1, 3 and 5.  Cells treated with 
AG490 maintained their cytoplasmic projections (black arrows) throughout the five days 
of culture-activation, whereas the control cells lost these processes as early as day 3.  
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Figure 3.5 Inhibition of JAK/STAT signaling pathway: cluster analyses. AMADA 
software was used to detect any relationships between the days in culture treated with or 
without AG490 over a 5 day period.  Distance relationships were calculated using 
Spearman rank correlation (D 0 - 2). The shorter the distance between two genes, the 
more similar the expression profile over days in culture.  Data from the treated cells (day 
1, 3 and 5) were incorporated with the previous data for days in culture (day Q – day 10) 
to demonstrate days of similarity based on gene expression.  The clustering showed the 
gene expression profile of HSCs treated with AG490 was highly related to the expression 
profile of the day Q HSCs.  
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Figure 3.6 Inhibition of JAK/STAT signaling pathway: genetic alterations of fibrotic 
markers.  mRNA expression of fibrotic genes from day 1, 3 and 5 (A-C respectively) 
culture-activated HSCs treated with or without AG490 were analyzed by RealTime PCR.  
Data were presented as mean ± SEM.  * p<0.05 compared to control.   
 
 
 
 
 
CHAPTER 4: MIRNA 19B: NOVEL BIOMARKER AND INHIBITOR OF HEPATIC 
STELLATE CELL-MEDIATED FIBROGENESIS 
 
Introduction 
Fibrosis of the liver is characterized by excessive deposition of extracellular 
matrix (ECM) components, predominantly type I collagen. Disproportionate deposition 
of fibrillar collagens disrupts normal liver architecture and hepatic function, and if left 
untreated, progresses to cirrhosis. Cytokine signaling predominates during fibrogenesis 
initiating activation of resident immune and hepatic stellate cells (HSCs)  promoting 
wound repair [83]. Activated HSCs are the principal cell type promoting synthesis and 
deposition of ECM proteins in response to increased levels of circulating inflammatory 
signals derived from damaged parenchymal cells. These resident vitamin A storing cells 
are found within the perisinusoidal space of Disse in a quiescent state, but upon hepatic 
injury, HSCs transdifferentiate into myofibroblast-like cells marked by expression of 
smooth muscle-actin (SMA) [16], loss of retinyl ester stores and neural marker glial 
fibrillary acidic protein (GFAP), and increased proliferation and contractility. 
Myofibroblastic HSCs respond to and secrete a variety of profibrogenic cytokines 
including connective tissue growth factor, tissue inhibitor of metalloproteinases and 
transforming growth factor- (TGF). Of these, TGF is recognized as the most potent 
fibrogenic cytokine regulating HSC collagen production via autocrine and paracrine 
signaling [32]. Numerous in vitro and in vivo studies report the importance of TGFβ 
signaling and that inhibition of TGF and/or its receptors decreases hepatic fibrosis and 
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HSC activation [85, 227].  In addition to induction of TGF signaling, numerous 
morphological and gene expression profile changes are acquired during 
transdifferentiation [94]. Recent epigenetic profiling of the transdifferentiation process 
highlighted a role for methyl CpG binding protein MeCP2, which was significantly up-
regulated upon culture-activation. Mechanistically, MeCP2 is reported to aid in the 
epigenetic reprogramming of the HSC through recruitment of silencing complexes to the 
promoter region of PPAR (known to maintain HSC quiescence) [128].  
microRNAs (miRNAs, miRs) are small non-coding RNAs which negatively 
regulate target gene expression through base pairing with 3’UTRs inducing mRNA 
cleavage or translational repression.  With multiple and diverse targets, miRs exert 
control over key cellular developmental processes including differentiation and 
proliferation. Specific contribution of select miRs in hepatic disease development and 
progression has been described [184]. Recent studies report the process of HSC 
transdifferentiation is governed by differential miRNA expression. Specifically, down-
regulation of miRNAs that control fat accumulation and adipocyte programming and up-
regulation of miRNAs that promote sustained activation of the cell concurrent with 
increased proliferation and suppression of apoptotic responses are observed [149, 228-
229]. Forced expression of miRs 150 and 194 in activated HSCs resulted in suppression 
of the fibrotic phenotype and inhibition of ECM production through downstream 
regulators of collagen expression [147]. Additional studies by Ogawa et al. reported 
direct regulation of collagen synthesis via binding of miR 29b to the 3’UTR of collagen 
and transcriptional regulator Sp1 in a human HSC line [150]. While the field continues to 
advance, studies to date have lacked accurate miR profiling of the divergent HSC 
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phenotypes in primary cells. Additionally, no studies have identified any miRs that have 
a global effect on profibrotic TGF signaling in the liver which could be more efficient 
than targeting a single gene.  
Herein, we report a set of differentially expressed miRs in quiescent (freshly 
isolated) vs activated HSCs, among which, miRNA 19b (miR 19b) directly inhibited 
fibrotic TGF signaling. Specifically, we validated computational prediction of miR 19b 
binding to the 3’UTR of TGFRII by luciferase reporter assay. miR 19b mimic 
significantly decreased expression of TGFRII as well as downstream target gene 
collagen, with additional suppression of markers of HSC activation (SMA and MeCP2) 
and concurrent increases in quiescent characteristics. In vitro findings translated to in 
vivo studies with decreased levels of miR 19b evident in fibrotic rat and human liver 
tissue compared to normal controls. These results identify miR 19b as a novel regulator 
of TGF signaling in HSC-mediated fibrogenesis and suggest a potential therapeutic 
approach for treating hepatic fibrosis. 
Results 
miRNA profiling in quiescent and activated hepatic stellate cells 
A total of 55 significantly differentially expressed miRs were identified by array 
analyses of quiescent (freshly isolated) and activated (day 14 of culture) HSCs. 
Validation of previously described miR expression levels was obtained, with miRs 16, 
29a/b/c, 150 and 194 all significantly down-regulated during culture activation (Figure 
4.1A, Table 4.S2). These experiments also identified ~20 differentially expressed miRs 
not previously reported in published array data available at the time of manuscript 
preparation (Table 4.S2). Analysis of differentially expressed miRs revealed members of 
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the miR-17-92 cluster (19a, 19b, 92a) were significantly down-regulated in the 
profibrotic activated phenotype. Based upon previous literature and in silico analyses 
(TargetScan and miRanda prediction databases), which predict putative seed match sites 
for miR 19b in the 3’UTR of TGFRII, this miR was selected for further analysis. qRT-
PCR confirmed array data, verifying a significant decrease of miR 19b in activated 
compared to quiescent HSCs (Figure 4.1B). Expression profile of miR 19b and predicted 
target mRNA TGFRII were followed over 14 days in culture and a significant inverse 
relationship was observed (Figure 4.1C) with a dramatic decrease seen in expression of 
the miR from quiescence to day 3 and a significant up-regulation of TGFRII.  
miR 19b negatively regulates profibrotic TGF signaling 
Activated HSCs were transfected with synthetic miR 19b (19b) or a miRNA 
mimic negative control (SCR) and following 24 or 48 h of transfection, RNA and protein 
were analyzed. Preliminary studies validated the SCR sequence did not significantly 
affect TGFRII expression or invariant control -actin compared to mock transfection or 
untransfected cells (Lipofectamine 2000 alone) (data not shown). Additionally, effective 
transfection of primary cells was verified by qRT-PCR and consistent concentration 
dependent increases were observed in miR 19b relative to 4.5S rRNA expression 
(Supplementary Figure 4.S1). TGFRII mRNA levels at both 24 and 48 h post-
transfection were significantly decreased compared to control, with greatest reduction 
seen when transfected with 75 nM 19b (Figures 4.2A and B). Similar results were 
observed in human HSCs (LX-2) (data not shown). Protein expression of the receptor 
was also significantly blunted by forced expression of miR 19b (Figure 4.2C).  
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Fibrotic TGF signaling propagates through the SMAD family of transcriptional 
activators, and like TGFRII, SMAD2 and SMAD3 are up-regulated following fibrotic 
liver injury [230]. While R-SMAD2/3 3’UTRs do not harbor putative miR 19b binding 
sites (as predicted by TargetScan and miRanda), mRNA expression of SMAD3 is 
significantly down-regulated after 48 h of miR 19b transfection (Figure 4.2D). miR 19b 
is also predicted to bind to the 3’UTR of Co-SMAD4, but no significant changes were 
observed in SMAD4 mRNA expression following transfections (Supplementary Figure 
4.S2). Computational prediction of miR 19b binding to the 3’UTR of TGFRII was 
validated by luciferase reporter assay (Figure 4.2E). Addition of miR 19b mimic induced 
a 50-60% reduction in luciferase activity compared to controls.    
miR 19b decreases expression of TGF target genes 
Effects of increasing miR 19b on downstream TGF signaling target procollagen 
mRNA and protein were measured. Forced expression of miR 19b dampened mRNA 
expression of both procollagen Col 1(I) and Col 2(I), with more significant effects 
observed on the transcription of Col 2(I) (Figures 4.3A and B). Translation of the 
fibrillar collagen is also markedly decreased after 48 h miR 19b treatment as denoted by a 
40% decrease in intracellular protein expression observed after 48 h (Figure 4.3C), 
confirming negative regulation of TGFRII signaling by miR 19b as both procollagen 
3’UTRs lack predicted binding sites (TargetScan). Additionally, functional secretion of 
this protein is disrupted by miR 19b as determined by immunoblot utilizing proteins 
concentrated from harvested culture medium (48 h) (Supplementary Figure 4.S3).  
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miR 19b Inhibits Paracrine TGF Signals  
Recombinant TGF1 was added to activated HSCs transfected with miR 19b 
mimics and levels of procollagen mRNA determined. Verification of collagen stimulation 
by addition of recombinant TGF1 protein was performed (data not shown). After 24 h 
Col 2(I) mRNA expression was decreased even in the presence of exogenous TGF and 
both procollagens were significantly decreased after 48 h of treatment as compared to 
respective control (Figure 4.4), indicating a powerful role for miR 19b in the 
inflammatory hepatic microenvironment.   
Markers of HSC activation are suppressed by miR 19b 
Forced expression of miR 19b blunted the activated HSC phenotype as denoted 
by shrunken cytoplasm, decreased polygonal shape and increased spindle shaped cellular 
protrusions  (characteristic of the quiescent phenotype) (Figure 4.5A). Morphological 
changes indicative of suppression of the activated phenotype correlated with levels of 
SMA mRNA, which were significantly decreased after 48 h of transfection (Figure 
4.5B). Immunoctyochemical analysis of SMA protein expression corroborated the 
visible reduction in activated phenotype as visualized by markedly reduced red 
fluorescence as well as by disorganization and disorientation of actin fibers (Figure 
4.5C). Further, miR 19b restored quiescent gene expression as evidenced by increased 
GFAP (Figure 4.5D). Levels of MeCP2 mRNA and protein were significantly reduced 
with increased expression of miR 19b (Figures 4.5E and F), highlighting a broad 
antifibrotic role for miR 19b.  
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miR 19b is decreased following fibrotic liver injury in vivo 
Next, we assessed whether decreased miR 19b also occurs in vivo (or in intact 
animals), in rat models of hepatic fibrosis. Tissue sections from BDL and sham operated 
control rats were subjected to in situ hybridization experiments to assess expression of 
miR 19b. miR 19b was markedly decreased in fibrotic liver tissue compared to controls 
(Figure 4.6A and B, Supplementary Figure 4.S4). miR 19b specific staining (dark blue 
chromagen) in control tissue appears outside of the parenchymal cells and higher 
magnification inspection is indicative of perisinusoidal (HSC-specific location) 
expression. Co-localization of miR 19b and HSC specific markers (GFAP and SMA) 
was attempted, but due to the nature of the punctate miR cytoplasmic expression and 
more dominant expression of HSC markers, chromagen-based co-localization was 
unsuccessful (paired IHC staining for HSC quiescent and activated markers appears in 
Supplementary Figure 4.S5). Interestingly, the decrease of miR 19b does not appear to be 
stimulus-specific, because in another rat model of liver injury/fibrosis 
(ethanol/lipopolysacchardide, ELPS [88]) hepatic miR 19b levels were also decreased 
(Figure 4.6C and D), strengthening the conserved importance of decreased miR 19b in 
hepatic fibrosis.  
Hepatic fibrosis is associated with decreased miR 19b in human liver 
Total RNA was isolated from fibrotic (Metavir fibrosis score of 3 or 4 due to 
varying etiologies including PBC, HCC and HCV) and normal control livers. qRT-PCR 
was used to determine relative expression levels of miR 19b. As observed in the rodent 
fibrotic injury models, levels of miR 19b were also significantly decreased by 
approximately 80% in human patients with fibrotic livers (Figure 4.7).  
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Discussion 
This study provides the first evidence that miR 19b has a functional role in rat and 
human liver fibrosis. Mechanistically, miR 19b acts as a novel inhibitor of fibrotic TGF 
signaling in the HSC and holds clinical promise as a therapeutic molecule and/or 
biomarker for fibrosis. Significant down-regulation of miR 19b was observed in activated 
HSCs as well as in rodent models of fibrosis and in human disease.  Forced expression of 
mature miR 19b in activated HSCs significantly reduced expression of TGFRII, which 
is vital for efficient activation of downstream profibrotic gene expression. Expression of 
procollagen mRNAs and secreted type I collagen were also markedly reduced by miR 
19b, even in the presence of exogenous TGF. In addition to regulating profibrotic gene 
expression, miR 19b impeded HSC activation and produced reversion to a more 
quiescent phenotype. miRs also exert indirect inhibitory actions on transdifferentiation 
through modulating epigenetic machinery [128]. Increased miR 19b significantly 
decreased MeCP2 expression, a factor necessary to suppress the quiescent phenotype of 
the cell.  
Although pathologies of chronic hepatic disease (ALD, HCV, HCC) are variable, 
fibrosis is an underlying commonality [2]. The exacerbated wound-healing response is 
characterized by excessive deposition of ECM components, predominantly type I 
collagen, by the activated HSC [3]. Fibrotic ECM remodeling disrupts normal hepatic 
architecture leading to organ dysfunction. Following exposure to a fibrogenic stimulus, 
numerous changes in cellular organization, gene expression and overall organ function 
can be observed. Damage to liver parenchyma results in hepatocyte necrosis and 
apoptosis with subsequent release of transforming growth factor beta (TGF). Following 
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liver injury, blood and tissue TGFβ levels are elevated stimulating collagen gene 
expression and additional downstream profibrotic targets including matrix degrading 
proteins. TGF is the most potent stimulus for HSC-mediated fibrogenesis [2, 231] as it 
plays a critical role in initiation of the transdifferentiation process. In addition to 
paracrine sources of the cytokine, TGF synthesis is markedly increased as a result of 
activation, further perpetuating the fibrotic phenotype.  Inhibition of TGF receptors 
(soluble TGFRII and knock-out models) and/or signaling components decreases HSC 
activation and dramatically blunts chronic wound-healing in experimental animal models 
[31-32, 84, 90]. These findings have established HSC-mediated TGFβ signaling as a 
pivotal mechanism in hepatic fibrogenesis and disruption of HSC activation and collagen 
deposition via inhibition of TGFβ signaling as a mechanism to ameliorate and/or reverse 
fibrosis. 
miRs have emerged as key regulatory molecules in chronic liver disease, 
including hepatic fibrosis [232-234]. Array profiling studies report differential miR 
expression in normal vs. fibrotic liver tissue in a variety of rodent injury models 
including BDL and CCl4 [235].  miRs 150, 187, 194 and 207 were significantly down-
regulated in HSCs isolated from BDL animals compared to sham controls, while let7 
family members were significantly up-regulated. Recently we have seen evidence that 
these small non-coding RNAs modulate fibrogenesis and HSC activation [184]. 
Overexpression of miRs 150 and 194 in human HSCs (LX-2) resulted in inhibition of 
proliferation as well as decreases in type I collagen and SMA [147].  
 miR profiling in human and murine liver fibrosis, and additional published in 
vitro manipulation studies, have highlighted a role for the miR 29 family in fibrosis via 
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regulation of collagen expression [150, 235]. While fibrosis underlies most chronic liver 
diseases, including HCV and ALD, when expression of miR 29 was examined in human 
samples, Roderburg et al. found expression of the miR highly variable amongst patients 
with viral vs alcohol-induced fibrosis, indicating the role of miR 29 in fibrosis may be 
stimulus specific [235]. Here we report that miR 19b levels are down-regulated in two 
experimental animal models of hepatic fibrosis (BDL, ELPS), and these results were 
confirmed in fibrotic human patients despite variable underlying etiology, supporting a 
highly conserved role of this miR in fibrosis. Moreover, success in identifying target 
genes of dysregulated miRs in liver disease has been limited. Herein, we report that miR 
19b binds to the 3’UTR of TGFRII directly inhibiting fibrotic HSC activation. Previous 
studies report miR expression patterns are organ and tissue specific, making systemic 
miR targeting problematic. However, recent reports have shown that miRs derived from 
the miR-17-92 cluster directly regulate TGF signaling in non-liver cell types, including 
neuroblastoma cells [236] and colonocytes [237]. Additionally, miR 19b levels are down-
regulated in fibrosis and ECM remodeling of other tissue/organs (pulmonary, cardiac) 
[238-239], indicating a highly conserved role of miR 19b in TGF-mediated 
fibrogenesis.  
In addition a very direct role in fibrogenesis through induction of pro-fibrotic 
target genes, TGF signaling may also be regulating expression profiles on a global level. 
miRs are processed from precursors molecules into pre-miRs within the nucleus. Once 
exported to the cytoplasm, the hairpin is cleaved by Dicer and strand selection occurs 
producing a mature miR available to associate with the RNA-induced silencing complex 
(RISC) [151]. Seminal studies have demonstrated miR biogenesis and processing are 
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directly controlled by constituents in the TGF pathway. Several miRs are post-
transcriptionally induced by TGF and nuclear accumulation of R-SMAD proteins 
promotes Drosha-mediated miR processing [152-153]. It would be of interested for future 
studies to investigate if increased levels of TGF observed in fibrosis affect disease 
pathology through HSC-mediated actions as well as by affecting global miR 
biogenesis/expression.   
Currently there are no FDA-approved treatments for fibrosis. As the field of miR 
research is rapidly developing, pioneering advances have emphasized there are critical 
changes in miR expression profiles during development of fibrosis which regulate 
wound-healing transcripts. While acknowledged that therapeutic modulation of single 
miRs in vivo has aimed to inhibit expression via antisense oligos/antagomirs, miR over-
expression strategies are also ongoing and hold great promise to restore delicate genetic 
programs vital to normal organ function. Adenoviral delivery of miR-17-92 cluster 
inhibited HCV replication in cell culture propogated HCV [240]. Additionally, recent 
reports in HCC demonstrate miR 26a administration is capable of repressing 
tumorigenesis without significant systemic effects [241], indicating that over-expression 
of miR 19b may be a useful therapeutic agent for TGF-mediated fibrosis.  
In addition to use as a therapy, miR 19b may also serve as an accurate biomarker 
of liver fibrosis and/or HSC activation. Several studies in settings of chronic liver disease 
with underlying fibrosis have shown strong correlations between specific miR expression 
patterns and responses to drug treatments as well as disease progression/prognostic 
outcome [184]. Plasma levels of miR 122 are elevated in both HBV and HCV patients as 
well as in models of alcohol and drug-induced liver damage reinforcing a role for miRs 
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as biomarkers [242]. Recent studies have also shown inverse correlations between tissue 
and plasma miR levels [242-243]. In fact, miR 19b was up-regulated 4.3-fold in serum of 
individuals with cirrhotic livers compared to normal controls [244] suggesting a 
potentially non-invasive route for diagnosing hepatic fibrosis. Future studies are needed 
to carefully monitor plasma miR 19b expression in relation to tissue from healthy 
individuals compared to varying fibrotic stages and etiologies.  
HCV represents the major cause of hepatic fibrosis on a global scale and is the 
most frequent indication of liver transplantation [245]; however, recurrent hepatitis C 
occurs in 80% of patients by 3 year post-transplant [246] and up to 20% advance to 
bridging fibrosis or cirrhosis within 2 years [247] due to TGF signaling and HSC 
activation [248-249]. Antiviral therapy with interferon and ribavirin in transplant 
recipients is only 10-30% effective, and therapy may not be well-tolerated. Identifying 
liver transplant recipients at greatest risk for rapid development of fibrosis from recurrent 
hepatitis C would target those recipients most urgently in need of antiviral therapy and 
defer treatment to those at less risk for disease progression [249]. In support of our 
findings, miR 19b levels were significantly higher in HCV responder vs non-responder 
patient populations, underscoring the importance of this specific miR [250]. Examining 
expression levels of miR 19b in HCV transplant patients could lead to development of a 
reliable marker to identify rapid progressors of fibrosis.  
Overall these systematic studies indicate that miR 19b is a novel regulator of fibrotic 
TGF signaling and indicates that the loss of miR 19b following HSC activation perpetuates 
the fibrotic response. Restored miR 19b expression in activated HSCs indicated this miR may 
be a possible therapy for the treatment or reversion of fibrosis, and patient data indicates this 
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powerful miR may prove to be an accurate biomarker for the fibrotic condition. These studies 
provide novel insight into the global regulation of a key signaling pathway which promotes 
hepatic fibrosis, and more importantly, provides a new avenue to be explored for translational 
research.  
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Figure 4.1 Differential miRNA expression in quiescent vs activated HSCs. (A) 
Microarray analysis for miRNA was performed with RNA extracts from primary 
quiescent (n=7) and activated (n=6) HSCs. Hierarchical cluster analysis of significantly 
differentially expressed miRs: bright green, underexpression; gray, no change; bright red, 
overexpression.  (B) Cells were harvested and miR 19b expression was determined in 
quiescent (n=7) and activated (day 14, n=6) HSCs as assessed by qRT-PCR. (C) qRT-
PCR analysis of miR 19b and TGFRII expression levels over days in culture (n=3) as 
normalized to 4.5S rRNA and -actin, respectively. Data are presented as mean ± SE. 
*Differs from quiescent vs activated, p<0.05. 
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Figure 4.2 miR 19b negatively regulates TGFRII expression. Day 6 HSCs were 
transiently transfected with miR 19b mimic (25-75 nM) and TGFRII gene expression 
was measured by qRT-PCR at (A) 24 h and (B) 48 h (n=4). Expression was normalized 
to -actin. (C) Representative immunoblot and quantitative densitometry of TGFRII 
protein expression 48 h post-transfection (miR 19b, 75 nM) (n=3). Expression was 
normalized to -actin. (D) R-SMAD gene expression in activated HSCs (day 6) 
transfected with mature miR 19b for 24 and 48 h was determined by qRT-PCR. (E) 
Inhibition of firefly luciferase activities of pEZX-TGFRII reporter by miR 19b mimic. 
LX-2 cells were co-transfected with 4.8 g of pEZX-TGFRII reporter plasmid or empty 
vector and 75 nM miR 19b mimic or SCR using Lipofectamine 2000. Data are presented 
as mean ± SE. *Differs from SCR, p<0.05. 
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Figure 4.3 miR 19b exerts inhibitory effects on TGF  target gene collagen.  Day 6 
HSCs were transiently transfected with miR 19b mimic (25-75 nM) and Col1(I) and 
Col 2(I) gene expression was assessed by qRT-PCR at (A) 24 h and (B) 48 h (n=4). 
Expression was normalized to -actin. (C) 48 h post-transfection cells were harvested and 
immunoblot performed on whole cell lysates for type I collagen expression.  Expression 
was determined by quantitative densitometry and normalized to -actin (n=3). Data are 
presented as mean ± SE. *Differs from SCR, p<0.05. 
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Figure 4.4 miR 19b inhibits paracrine TGF signals. Day 6 activated HSCs were 
transfected with or without miR 19b mimic (75 nM) and following standard 6 h 
incubation, transfection medium was removed and fresh culture medium devoid of 
antibiotic was added that contained 5 ng/mL of recombinant TGF (rhTGF) for a period 
of 48 h. Cells were harvested and mRNA levels of Col 1(I) and Col 2(I) were assessed 
by qRT-PCR (n=3). Data are presented as mean ± SE. *Differs from rhTGF control, 
p<0.05. 
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Figure 4.5 HSC activation is inhibited by miR 19b. (A) Activated HSCs (day 6) were 
transfected with negative control (SCR) or miR 19b (75 nM) for 48 h. Cell morphology 
was visually assessed and representative light micrographs (40X) are shown. (B) Day 6 
HSCs were transiently transfected with miR 19b mimic (75 nM) and SMA gene 
expression was assessed by qRT-PCR at 24 h and 48 h (n=4). (C) Representative images 
(40X) of fluorescent immunocytochemical analysis of SMA expression (red) in 
activated HSCs following 48 h of transfection with SCR or miR 19b mimic (75 nM); dapi 
staining (blue) was used to indicate cell nuclei (n=3). (D) Day 6 HSCs were transiently 
transfected with miR 19b mimic (75 nM) and GFAP expression was assessed by qRT-
PCR at 48 h (n=4).  (E) MeCP2 gene expression as measured by qRT-PCR following 24 
h of miR 19b transfection in activated HSCs (day 6) (n=4). (F) Representative 
immunoblot and quantitative densitometry of MeCP2 protein expression in HSCs (day 6) 
following 48 h of miR 19b (75 nM, n=3). Expression was normalized to -actin.  Data 
are presented as mean ± SE. *Differs from SCR, p<0.05. 
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Figure 4.6 Down-regulation of miR 19b in rodent models of hepatic fibrosis. 
Representative light micrographs (40X) of liver tissue sections following in situ 
hybridization with double DIG labeled LNA miR 19b probes. miR 19b expression levels 
are marked by dark blue chromagen staining (denoted by black arrows). (A-D) miR 19b 
expression in normal and fibrotic liver tissues. (A and B) Liver tissues harvested from 
rats which underwent BDL or sham surgeries (tissue harvested at 2 weeks). (C and D) 
Liver tissue harvested from controls and rats fed ethanol with bi-weekly injections of 
LPS [88].  
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Figure 4.7 miR 19b is a putative biomarker for human hepatic fibrosis. RNA was 
harvested from normal (n=7) and fibrotic (n=21) human liver tissue and miR 19b 
expression was assessed by qRT-PCR. Expression was normalized to SNORD44. Data 
are presented as mean ± SE. *Differs from control, p<0.05. 
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Table 4.S1 Primers used in this study. 
 
 
Gene Forward Reverse 
-actin  
 
GAGCTATGAGCTG
CCTGACG 
GGATGTCAACGTC
ACACTTC 
Collagen α1(I) (col  α1(I)) 
 
CACTGCAAGAACA
GCGTAGC 
ATGTCCATTCCGAA
TTCCTG 
Collagen α2(I)  (col 1(I)) 
 
AAGGCATTCGAGG
ACACAAC 
TTACCAACAGGCCC
AAGTTC 
Glial fibrillary acidic protein 
(GFAP) 
AGAAAACCGCATC
ACCATTC 
TTGGGCCTAGCAA
ACAAGAC 
Methyl CpG binding protein 2 
(MeCP2) 
TGCTGCTGCCTTTG
GTCT 
TTGAAAAGGTGGG
AGACA 
SMAD2 TGGTAAGAAAATG
TCGTCCATC 
TTTCAGAGCAAGTG
CTTGGTAT 
SMAD3 GTGACACTCCTGAA
GGCCATAC 
GGCCAACAAAGAG
GGTTCTAGT 
SMAD4 AAGGACAGCCATC
CTTACCC 
GCCCTGAAGCTATC
TGCAAC 
Smooth muscle-actin 
(SMA) 
CATCAGGAACCTC
GAGAAGC 
TCGGATACTTCAGG
GTCAGG 
Transforming growth factor  
receptor II (TGFRII) 
TCACTAGGCACGTC
ATCAGC 
AGGACAACCCGAA
GTCACAC 
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Table 4.S2 List of differentially expressed miRs detected in activated vs. quiescent 
HSCs.  
 
Probeset ID p-value(activated vs. quiescent) Fold-Change (activated vs. quiescent) 
rno-miR-122_st 7.3E-05 -3.7E+02 
rno-miR-126_st 5.4E-10 -6.7E+01 
rno-miR-139-3p_st 2.1E-04 -7.5E+00 
rno-miR-139-5p_st 1.0E-04 -6.8E+00 
rno-miR-140-star_st 3.4E-03 -2.5E+00 
rno-miR-150_st 8.2E-09 -7.5E+01 
rno-miR-151_st 3.9E-07 -2.1E+00 
rno-miR-16_st 5.3E-06 -2.2E+00 
rno-miR-192_st 9.3E-05 -7.8E+01 
rno-miR-194_st 9.0E-05 -6.7E+01 
rno-miR-195_st 8.2E-07 -1.7E+01 
rno-miR-19a_st 2.2E-03 -1.5E+00 
rno-miR-19b_st 2.8E-05 -6.3E+00 
rno-miR-203_st 1.9E-05 -3.1E+00 
rno-miR-25_st 2.5E-05 -4.2E+00 
rno-miR-26a_st 2.8E-06 -2.7E+00 
rno-miR-29a_st 1.9E-04 -2.5E+00 
rno-miR-29b_st 1.2E-04 -5.2E+00 
rno-miR-29c_st 5.1E-04 -3.1E+00 
rno-miR-30a-star_st 3.1E-04 -6.3E+00 
rno-miR-30a_st 2.1E-04 -4.1E+00 
rno-miR-30b-5p_st 4.4E-06 -6.9E+00 
rno-miR-30c-2-star_st 6.9E-04 -6.4E+00 
rno-miR-30c_st 1.6E-07 -4.8E+00 
rno-miR-30d_st 3.4E-05 -3.3E+00 
rno-miR-30e_st 1.2E-04 -8.2E+00 
rno-miR-322-star_st 2.8E-03 -3.8E+00 
rno-miR-322_st 9.5E-04 -3.6E+00 
rno-miR-339-3p_st 1.5E-05 -5.7E+00 
rno-miR-378-star_st 3.0E-03 -5.0E+00 
rno-miR-378_st 3.8E-03 -4.5E+00 
rno-miR-497_st 9.5E-06 -1.8E+01 
rno-miR-532-3p_st 6.4E-04 -3.7E+00 
rno-miR-532-5p_st 2.5E-05 -1.8E+01 
rno-miR-872-star_st 1.0E-03 -2.2E+00 
rno-miR-92a_st 3.1E-05 -2.0E+00 
rno-miR-99a_st 1.7E-03 -3.3E+00 
rno-miR-125b-3p_st 1.6E-06 7.4E+00 
rno-miR-125b-5p_st 9.0E-06 2.0E+00 
rno-miR-132_st 2.4E-05 1.3E+01 
rno-miR-143_st 1.5E-05 3.0E+00 
rno-miR-145_st 2.6E-04 2.6E+00 
rno-miR-152_st 1.5E-06 3.3E+00 
rno-miR-184_st 2.7E-05 1.5E+01 
rno-miR-185_st 8.7E-04 2.7E+00 
rno-miR-199a-3p_st 1.1E-04 3.8E+00 
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rno-miR-199a-5p_st 3.4E-08 6.0E+00 
rno-miR-210_st 1.9E-04 1.2E+01 
rno-miR-214_st 3.9E-08 8.0E+00 
rno-miR-221_st 1.5E-05 1.1E+01 
rno-miR-222_st 2.7E-07 1.7E+01 
rno-miR-31_st 2.1E-03 1.5E+01 
rno-miR-34b_st 1.6E-03 2.2E+00 
rno-miR-34c-star_st 6.7E-04 9.4E+00 
rno-miR-34c_st 6.7E-05 2.7E+01 
rno-miR-99b_st 1.9E-06 2.4E+00 
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Figure 4.S1 Efficient transfection of miR 19b in activated HSCs. Representative qRT-
PCR analysis of miR 19b expression in HSCs  transfected with Lipofectamine 2000 alone 
(LIPO), negative control (SCR) or mature miR 19b (25-75 nM) for 24 h. Expression was 
normalized to r RNA. Data are presented as mean ± SE. *Differs from SCR, p<0.05. 
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Figure 4.S2  miR 19b does not affect SMAD4 gene expression in activated HSCs. 
qRT-PCR analysis of SMAD4 gene expression following 24 h of miR 19b transfection 
studies as normalized to levels of -actin (n=3).  
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Figure 4.S3 Collagen secretion is inhibited by miR 19b in activated HSCs. 
Quantitative densitometry of immunoblot analyses of secreted type I collagen protein 
expression following 48 h of miR 19b (75 nM) transfection in HSCs (day 6). Culture 
medium was harvested following 48 h and proteins concentrated using Nanosep tubes 
(Pall Corporation; Ann Arbor, MI). Concentrated protein (10 g) was used for standard 
immunoblotting analysis. Quantitative densitometry of secreted type I collagen was 
performed and normalized to total protein (n=3). Data are presented as mean ± SE. 
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Figure 4.S4 In situ hybridization of miR 19b in normal and fibrotic rat liver.  Liver 
sections from a BDL model of hepatic fibrosis (sham, top panel; BDL, bottom panel). 
miR 19b expression levels are marked by dark blue chromagen staining. Representative 
light micrographs (20X) of liver tissue sections. 
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Figure 4.S5 Immunohistochemistry of quiescent and activated markers of HSCs. 
Liver sections from two models of hepatic fibrosis [BDL; top panels, Ethanol/LPS 
(ELPS); bottom panels]. Quiescent and activated HSCs were detected by GFAP and 
SMA staining, respectively (brown chromagen) and counterstained with methyl green. 
 
 
 
 
 
CHAPTER 5: ALTERED AQUAPORIN EXPRESSION AND ROLE IN 
APOPTOSIS DURING HEPATIC STELLATE CELL ACTIVATION 
 
 
 
Introduction 
Hepatic fibrosis is characterized by an accumulation of secreted type I collagen by 
hepatic stellate cells (HSCs) [15-16]. Within the liver, fibrosis is mediated by a number 
of factors including viral infection, genetic disease, and/or xenobiotic-induced damage. In 
the normal liver HSCs reside in a quiescent state, functioning to store vitamin A, 
modulate the microcirculation, and regulate extracellular matrix production. Following 
injury, the HSCs transdifferentiate into an activated myofibroblast-like cell characterized 
by loss of vitamin A droplets, increased smooth muscle- actin expression (-SMA), and 
decreased sinusoidal blood flow. Continued HSC transdifferentiation leads to collagen 
deposition, persistent activation, increased proliferation, and diminished responsiveness 
to apoptotic stimuli [52]. Reversal of hepatic fibrosis has been reported and is dependent, 
at least in part, on the induction of HSC apoptosis [48]. 
 Apoptosis is characterized by a highly conserved series of biochemical and 
morphological events initiated by the apoptotic volume decrease (AVD). During the 
AVD intracellular K+ levels decrease from 140mM to < 35mM, a pre-requisite for 
downstream caspase and nuclease activation [159-160]. These, and other, changes in 
intracellular solute concentrations, result in the creation of a sustained osmotic gradient 
and net water loss from the cell resulting in the cell “shrinkage” characteristic of all 
apoptotic cells [159, 161].  
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 Aquaporins (AQPs) are a family of transmembrane proteins that are ubiquitously 
expressed in plant and animal cells [163]. To date 13 mammalian AQP homologs (AQP 
0-12) have been identified, which have been functionally subdivided based on solute 
transported (e.g. aquaporins and aquaglyceroporins) [165, 251]. Studies using knockout 
mice demonstrate the importance of AQPs in regulating a wide array of cell functions in 
a range of organ systems including the liver [167, 252-253]. Previous studies demonstrate 
water movement during the AVD occurs via AQPs [159-160, 162], and inhibition of 
AQP-dependent water movement during the AVD significantly slows apoptotic 
progression [160-161, 164]. At least 7 AQP homologs have been identified in the liver 
and play important roles in hepatobiliary physiology and patho-physiology [162, 167].  
 No studies, to our knowledge, have addressed the expression or function of AQPs 
in HSCs. Given the importance of AQPs during the initiation and progression of 
apoptosis [159-160, 162], and the role of HSC apoptosis during the regression of hepatic 
fibrosis [48], we hypothesized that sustained HSC activation and increased cell survival 
in activated HSCs may be due to changes in AQP expression and/or function.  
Results 
Decreased AQP expression in activated versus quiescent HSCs 
Analysis by RT-PCR detected the expression of AQP 0, 1, 5, 8, 9, 11, and 12 
mRNAs in dQ HSCs. In contrast, culture-activated (d14) HSCs were characterized by the 
presence of AQP 0 and 11 mRNA and a failure to detect AQP 1, 5, 8, 9 or 12 mRNA 
(Figure 5.1A). mRNA for the remaining AQP homologs (AQP 2, 3, 4, 6, 7, and 10) were 
detected in positive control samples but not detected in either dQ or d14 HSCs (data not 
shown). Since AQP 8 and 9 are prominently expressed in dQ HSCs and represent two 
subclasses of proteinacious AQP channels, gene expression of both homologs was 
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determined over 10 days in culture to measure changes in expression during HSC 
activation. Consistent with RT-PCR, RealTime analyses showed dQ HSCs to have 
significantly higher expression of AQPs 8 and 9 compared to all other days in culture, 
with the most dramatic decline in expression occurring from dQ to d1 (Figure 5.1B).    
To determine AQP protein expression Western blot analyses were performed for 
those AQPs detected at the mRNA level in dQ and/or d14 HSCs. Using this approach, we 
failed to detect AQPs 0, 1, 8, and 9 protein in d14 HSCs (Figure 5.1C) (albeit at very long 
exposures a faint band appeared for AQP 8 and 9, data not shown). Conversely, AQP 11 
was clearly detectable in d14 HSCs, an effect not evidenced in dQ HSCs. Despite 
detecting AQP 5 mRNA and protein in control tissue (rat kidney) and AQP 5 mRNA in 
dQ HSCs, we were unable to detect AQP 5 protein expression in either dQ or d14 HSCs, 
even following prolonged film exposure times (20-25 minutes, Figure 5.1C). Finally, we 
were unable to detect AQP 12 protein expression in either HSCs (dQ or d14) or positive 
control tissue (rat pancreas) extracts using commercially available antibodies (data not 
shown).  
Plasma membrane water permeability is AQP-dependent in HSCs 
To ascribe AQP functionality in HSCs, we next determined cell membrane water 
permeability with or without AQP inhibitor pre-treatment; HgCl2 (100M; 2 minutes), 
concomitant with rapid osmotic challenge (210 mOsm; 30 seconds). In dQ HSCs osmotic 
challenge significantly increased cell swelling as evidenced by increased mean cell size 
and a “shift” in cell distribution/forward scatter (Figure 5.2A and B, p<0.005). The effect 
of osmotic challenge on dQ HSCs was abrogated by pre-treatment with HgCl2 (100 M; 
2 minutes, Figure 5.2A and B). Conversely, d14 HSCs demonstrated a failure to 
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significantly respond to osmotic challenge compared to freshly isolated HSCs, an 
observation that was not significantly affected by pretreatment with HgCl2 (100 M; 2 
min, Figure 5.2A and B). 
 AQP-dependent morphological responses to apoptotic stimulus 
Treatment of dQ HSCs with GTx led to dramatic and rapid (20 minutes) 
decreases in cell surface attachment, accompanied by loss of cytoplasmic projections at 
both doses of GTx tested (0.15 or 1.5 µM, Figure 5.3A). In contrast, similar anoikis-like 
effects in d14 HSCs were only observed after 60 minutes of GTx treatment and only at 
the higher dose employed (1.5 µM) (Figure 5.3B). To determine if the effects of GTx 
were dependent on AQP expression/function, dQ and d14 HSCs were treated in parallel 
with HgCl2 (100M; 15 min) prior to GTx exposure. Under these experimental 
conditions no cell detachment was observed following 0.15 or 1.5 µM GTx treatment. 
Furthermore, dQ HSCs pre-treated with HgCl2 maintained morphological integrity, as 
characterized by the presence of cytoplasmic projections, indicating the maintenance of a 
quiescent/early activation phenotype. Pre-treatment of d14 HSCs with HgCl2 did not 
stimulate changes in cell morphology/phenotype (myofibroblast-like) either in the 
absence or presence of GTx (Figure 5.3A and B). Direct cell counts and trypan blue 
exclusion assay during treatment with 1.5 µM GTx showed significantly decreased cell 
viability in dQ HSCs 20 min after GTx compared to d14; HgCl2 pre-treatment abrogated 
this effect (Figure 5.3C and D). Trypan blue exclusion studies confirmed pre-treatment 
with HgCl2 did not adversely affect HSC viability (93 ± 4 % and 95 ± 2% viability 60 
minutes after HgCl2 treatment, dQ and d14 HSCs, respectively). 
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Inhibition of AQP channels decreases apoptotic response 
To further elucidate the morphological response to apoptotic challenge, caspase-3 
activity was measured. Treatment of dQ HSCs with GTx (1.5 µM) led to significant 
increases in caspase-3 activity 20 minutes after GTx stimulation before decreasing over 
the following 40 minutes (Figure 5.4A). In contrast, no significant increase in caspase-3 
activity was observed in d14 HSCs until 45 minutes after GTx stimulation, and the 
increase in caspase-3 activity was transient (Figure 5.4A). Pre-treatment of dQ and d14 
HSCs with HgCl2 (100 µM; 15 minutes) abrogated the effect of GTx on caspase-3 
activity at all of the time points measured (Figure 5.4A, p<0.05). Pre-treatment of dQ and 
d14 HSCs with Z-VAD (pan-caspase inhibitor) demonstrated that subsequent GTx 
treatment failed to significantly stimulate caspase-3 activity in either dQ or d14 HSCs 
(Figure 5.4A). Western blot analyses confirmed these results, PARP cleavage being 
decreased in d14 HSCs as compared to dQ HSCs, effects that were abolished by HgCl2 
pre-treatment (Figure 5.4B).  
Decreased AQP expression in activated versus quiescent HSCs in a model of liver 
injury 
Dual fluorescent immunohistochemical staining was performed to measure AQP 
expression in activated and quiescent HSCs in vivo. GFAP and α-SMA were used as 
markers of quiescent and activated HSCs, respectively. Merged images confirmed 
increased colocalization of quiescent HSCs with both AQP 8 and 9 in control (CTRL) 
liver tissue as indicated by yellow fluorescence (Figure 5.5A and E). Conversely, in 
injured liver (ELPS) tissue GFAP positive quiescent HSCs were decreased [as indicated 
by the lack of green fluorescence in Figure 5.5C and G] while α-SMA (a hallmark of 
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activated HSCs) expression increased. However, a lack of colocalization of α-SMA 
positive cells with AQP 8 and 9 expression was observed, as indicated by the lack of 
yellow fluorescence in merged images (Figure 5.5D and H). 
Discussion  
Several studies have reported the specific expression of AQP homologs in 
different hepatic cell populations (as reviewed by Masyuk and LaRusso [167]). However, 
to our knowledge, no studies have addressed the specific expression, or functional 
significance, of AQPs in the hepatic stellate cell (HSC). In this report we describe the 
expression profile of aquaporin (AQP) homologs in HSCs in vitro, and the changes that 
occur in AQP expression between quiescent and activated HSCs. Specifically we report 
quiescent HSCs are characterized by AQP 0, 1, 8 and 9 expression at the mRNA and 
protein level. Conversely, only AQP 11 was detected at both the mRNA and protein level 
in activated HSCs. Using osmotic challenge, in the absence and presence of a non-
specific AQP channel blocker (HgCl2), we demonstrated rapid AQP-dependent water 
movement across the plasma membrane in quiescent HSCs indicating the presence of 
functional AQP homologs within the plasma membrane. Conversely, activated HSCs 
failed to respond to osmotic challenge. We demonstrated that quiescent HSCs (4 hours), 
expressing multiple AQP homologs, were significantly more responsive to apoptotic 
stimulation (gliotoxin; GTx) versus activated HSCs. Finally, confirming in vitro studies, 
fluorescent immunohistochemistry showed strong colocalization between quiescent 
HSCs and AQPs 8 and 9, while α-SMA positive HSCs found in injured liver tissue 
exhibit dramatically decreased AQP expression. 
 116
The amelioration of hepatic fibrosis has been attributed to decreasing the presence 
of HSCs at the site of injury through apoptotic cell death [48, 154]. Additionally, upon 
cessation of the fibrogenic stimulus, activated HSCs are thought to undergo apoptosis, 
removing the source of continued ECM deposition without eliciting an inflammatory 
response [173]. There has been considerable interest in determining the molecular events 
that regulate HSC apoptosis. Activated HSCs have been reported to demonstrate 
increased resistance to apoptosis due to increased bcl-2 expression [52]. However, 
activated HSCs are still capable of undergoing apoptosis in response to a variety of 
stimuli including gliotoxin, superoxide, and tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) [169-170, 173, 254]. In general, studies have been inconsistent 
when examining the two HSC phenotypes (quiescent and activated) in vitro. Studies 
either did not compare the rate of apoptosis in the activated state to quiescent HSCs, or if 
they did, the comparison was made to HSCs 48 hours after initial isolation and culture 
[169]. In contrast, our studies utilized freshly isolated HSCs for expression analysis or 
within 4 hours of performing functional studies. Our data demonstrate that quiescent 
HSCs express more AQP homologs, are more susceptible to osmotic challenge, and 
respond more rapidly and to lower doses of GTx than do fully activated, 14 day cultured 
HSCs. Interestingly, studies in a rat model of hepatocellular carcinoma demonstrated 
increased AQP 8 and 9 expression following isolation from the tumor and culturing in 
vitro. These changes in AQP expression correlate accordingly with altered 
responsiveness to osmotic and apoptotic challenge [162].  
Several studies that modulated AQP expression demonstrated overexpression of 
specific homologs leads to increased migratory capacity and cell proliferation [255]. 
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Additionally, AQP 1 and 3 knockout mice exhibited significant impairment in wound-
healing and in urinary concentrating function [251, 253]. Our studies demonstrate that 
while AQPs 0, 1, 8 and 9 were detected at the mRNA and protein level in freshly isolated 
HSCs, AQP 5 and 11 were only detected at the mRNA level. Conversely, the only AQP 
we were able to detect at the mRNA and protein level in the activated HSCs was AQP 11. 
This raises several important questions that require further analysis experimentally. 
Firstly, what is the endogenous function of AQPs in quiescent HSCs in vivo? The 
majority of studies of AQP expression and function focus on organ systems that require 
the regulation of high levels of water movement as an integral part of physiological 
function (e.g. kidney, eye). Similarly, within the liver, the majority of work to date has 
focused on the role of hepatocyte AQPs (AQP 8 and 9) in regulating bile synthesis and 
modification [256-257], no discernable function having been identified for AQP 0, the 
other AQP homolog reported (ostensibly in the cytoplasm) of pericentral hepatocytes 
[258]. In contrast, quiescent HSCs in the healthy liver would not appear to require a high 
physiological demand for rapid water movement; however, AQP expression may be 
necessary for other functions such as migration and proliferation in response to injury 
[251] since 4 different AQP proteins and 7 different AQP mRNAs are expressed.  
Secondly, AQP 5 and 11 mRNA were detectable in quiescent HSCs, yet we failed 
to detect the corresponding proteins. One possible explanation for this may lie in the 
ubiquitous expression and highly conserved nature of AQPs whereby mutation of the 
gene encoding one AQP homolog may have such dire, and rapid, consequences on cell 
function that an inherent “redundancy” exists. This does not, however, explain our 
observation that AQP 11 is clearly expressed in activated HSCs yet appears to play no 
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discernable role in mediating transmembrane water movement (as attested by the failure 
of activated HSCs to respond to osmotic or apoptotic stimulation). Interestingly, AQP 11 
is characterized by an unusual NPA-pore forming motif [259] and controversy exists as 
to its water transport capabilities and function [260-262].  
In contrast to the quiescent HSC, when stimulated to transdifferentiate, proliferate 
and undergo activation by culture on plastic, HSCs were characterized by marked 
decreases in net AQP expression. One possible explanation for this may be an absolute 
requirement for the activated HSC (in vivo) to demonstrate sustained resistance to 
apoptosis in the face of severe and/or prolonged hepatic insult. In doing so the HSC 
would thus maintain the ability to synthesize/secrete ECM as an integral part of the net 
hepatic protective response. Alternatively, it is possible that the process of matrix protein 
degradation, cell isolation and purification may also play a part in regulating both AQP 
expression and/or localization. AQP functionality is regulated by cellular/membrane 
localization, insertion into the plasma membrane creating an “unregulated”, bi-directional 
channel for water movement, the net direction of movement being dependent on the 
osmotic gradient [163, 165]. As such, during the process of removing HSCs from the 
native, complex 3-dimensional environment of the hepatic sinusoid may be sufficient to 
initiate changes in AQP mRNA and/or protein expression. 
In summary, these data demonstrate that HSCs express AQPs and suggest that 
regulation of AQP expression/function contributes to HSC susceptibility to an apoptotic 
challenge. These data indicate it will be of considerable interest to study AQP expression 
and apoptosis in HSCs using animal models of progressive liver injury in which the 
magnitude and duration of the hepatic insult can be manipulated. In doing so, direct or 
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indirect modulation of AQP expression in HSCs may lead to the development of novel 
therapeutics for the treatment of hepatic fibrosis.  
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Figure 5.1 Aquaporin expression in quiescent and activated HSCs. (A) 
Representative RT-PCR analyses of AQP mRNA expression. Analysis of AQPs 2, 3, 4, 
6, 7, and 10 revealed no detectable message. (B) Quantitative analysis of AQP 8 and 9 
mRNA expression over 10 days in culture assessed by RealTime PCR (relative to dQ); 
*p<0.05 as compared to d1-d10. (C) Representative immunoblot analyses of samples 
prepared from quiescent (dQ) and activated (d14) HSCs using antibodies specific against 
AQP 0, 1, 5, 8, 9, and 11. (+) tissue positive control; liver tissue for AQPs 0, 1, 4, 8, 9 
and 11; kidney tissue for AQPs 1, 2, 3, 5, 6, 7 and 10; pancreas tissue for AQP 12; small 
intestine tissue for AQP 10; (-) water (n=3).  
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Figure 5.2 HSC plasma membrane water permeability. (A) Representative cell 
swelling analysis histograms of dQ and d14 HSCs in normotonic (black) and hypotonic 
(grey line overlay) solutions. Samples were pre-treated with or without the AQP channel 
blocker HgCl2 (100 µM; 2 minutes). (B) Quantitative analysis of cell swelling in dQ or 
d14 cells (n=4) * p<0.05 as compared to control, #p<0.05 versus HgCl2 + Osm (osmotic 
challenge). 
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Figure 5.3 Morphological response to an apoptotic stimulus. Cells were treated with 
gliotoxin (GTx; 0.15 or 1.5 µM) or vehicle alone. Samples were pre-treated with or 
without the AQP channel blocker HgCl2 (100 µM; 15 minutes). (A) Morphology of dQ (4 
hours) and d14 HSCs were assessed after 20 minutes under 20X magnification (n=4). (B) 
Morphology of dQ (4 hours) and d14 HSCs after 60 minutes (n=4). (C,D) dQ and d14 
cell viability was assessed by direct cell counts and trypan blue exclusion assay at the 
indicated time points following exposure to 1.5 µM GTx. Percent remaining cells was 
calculated (remaining adherent cell number/vehicle x 100); *p<0.05 as compared to 
HgCl2 treated samples, #p<0.05 within treatment group. 
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Figure 5.4 Effect of aquaporin channel inhibition on caspase-3 activity. (A) Caspase-
3 activity in dQ (4 hours) and d14 HSCs. Cells were treated for 20, 45, or 60 minutes 
with vehicle or gliotxin (GTx; 1.5 µM). Cells were pre-treated with or without HgCl2 
(100 µM; 15 minutes). The pan-caspase inhibitor Z-VAD-FMK (Z-VAD) was added as 
control (n=3). *p<0.05 as compared to HgCl2 treated samples; #p<0.05  within treatment 
group. (B) Representative immunoblot analyses of samples prepared from dQ and d14 
HSCs using an antibody specific against the cleaved fraction of PARP (89 kDA). Cells 
were treated for 20, 45, or 60 minutes with vehicle or gliotxin (GTx; 1.5 µM) and were 
pre-treated with or without HgCl2 (100 µM; 15 minutes) (n=2).  
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Figure 5.5 HSC aquaporin expression in a model of liver injury. Dual fluorescent 
immunohistochemistry was performed on liver tissue (20X magnification with 40X 
insets) using an ethanol/LPS (ELPS) injury animal model.  Sections (4m) from ELPS 
(C, D, G, H) or control (CTRL, A, B, E, F) were incubated with primary antibody 
cocktail. Aquaporin immunoreactivity is shown in red (AQP 8 panels A-D, AQP 9 panels 
E-H); GFAP and α-SMA (shown in green) were used as markers of quiescent and 
activated HSCs, respectively. Colocalization is indicated by yellow fluorescence.  
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Table 5.S1 Primers used in this study. 
Gene Forward Reverse 
AQP 1 CATGAAGGTGTGGACCAGTG CCAGGAAGCTCTGAGACCAG 
AQP 2 GGTTCCCAGTGCAGAGTA GCGGAGACGAGCACTTTTAC 
AQP 3 AGGAGTTGATGAACCGTTGC AAGCCAAGTTGATGGTGAGG 
AQP 4 AGAGCATCATGGTGGCTTTC CGATGCTGATCTTTCGTGTG 
AQP 5 TCTGGGTAGGGCCTATTGTG CAGCTCGATGGTCTTCTTCC 
AQP 6 TCAAGAGACCAGGAGGATCG GCCAGGAACTCAGCAAAAAG 
AQP 7 ATCCTTGTTTGCGTTCTTGG AGAACCCTGTGGTGGTATGC 
AQP 8 TCATTGCTACCTTGGGGAAC GCTCCTGCTCCTGGACTATG 
AQP 9 CGCCAGGTGCCTTTGTAG GAAGACCTCAAACCCCATC 
AQP 10 GCGAGCTCTCTGGCTGTTAC AGGGACAGATATGGGGAAGG
AQP 11 CCTTCCAGCTCTGCTACTGC GGTACTTGGTCAGGCTCAGG 
AQP 12 GGGAGCTCAGCGAACTACAC AGGTGTTCCCAGAACAGTGG 
 
 
 
 
 
 
 
CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS 
 
In a normal healthy liver, HSCs are found in the quiescent phenotype and reside 
in the space of Disse. Quiescent HSCs store vitamin A in the form of retinyl esters, 
regulate hepatic sinusoidal microcirculation, and maintain basement membrane 
conditions. Following exposure to fibrogenic stimuli, HSCs transdifferentiate to activated 
myofibroblast-like cells characterized by increased proliferative and hypercontractile 
properties. The activated phenotype is marked by loss of retinyl ester stores and star-like 
morphology and expression of myofibroblast marker SMA [4, 16]. Initiation of HSC 
activation is driven by increased circulating proinflammatory molecules. Upon migration 
to sites of injury, HSCs not only respond to, but secrete a wide range of proinflammatory 
cytokines, most notably TGF. In facilitation of wound-healing, HSCs produce and 
secrete ECM products to repair damaged tissues. Withdrawal of noxious stimuli results in 
a reduced number of activated HSCs, with the fate of activated cells unknown; 
speculation has indicated induction of apoptosis or reversion to quiescence [2]. However, 
in states of chronic injury, accumulation of ECM components, predominately type I 
collagen, disrupts normal liver architecture impairing nutrient delivery, 
metabolic/detoxification functions, and sustains the inflammatory milieu, culminating in 
hepatic fibrosis. With fibrosis unresolved, progression to end-stage liver disease 
(cirrhosis) is observed. While removal of underlying stimuli or treatment of fibrosis can 
result in reversion of the disease state, this is not the case for cirrhotic patients. Currently, 
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there are no FDA-approved treatment regimes for hepatic fibrosis, underscoring the 
importance of development of novel therapeutic strategies [3, 15].  
The process of HSC transdifferentiation has been studied intensely to determine 
points of therapeutic intervention. While cellular and molecular events characterizing 
initiation and perpetuation phases have been described, there is still much to be learned 
about specific properties unique to each HSC phenotype that could be exploited for 
therapeutic development. Overview of the literature indicates clearly there is not a 
common cure-all for HSC-mediated fibrosis. Therefore, examination of multiple points of 
HSC transdifferentiation is necessary to uncover novel targets and/or avenues for 
combination therapies.  
Examining specific genes and/or cellular signaling pathways involved in initiation 
of  HSC transdifferentiation is imperative. However, for these findings to have impact it 
is of even greater importance that divergent phenotypes of the HSC be clearly defined. 
While studying the process of HSC transdifferentiation is difficult to monitor in vivo, 
culturing these cells on plastic substrates to mimic increased matrix stiffness remains a 
widely accepted technique. Unfortunately, past and ongoing studies examining quiescent 
and activated HSCs have convoluted the terminology [214, 263]. Isolation of primary 
HSCs from rodents and subsequent culturing of the cells on plastic leads to a transition 
from quiescent to fully-activated myofibroblasts [264-265]. However, the term 
“quiescent” has been utilized to indicate varying stages of HSC activation and culture. 
While some use the term to describe cells that have been in culture for 24 hours, others 
state cells are quiescent up to 3 days on plastic. However, it has been shown by our lab 
and others that plating HSCs on plastic for as few as 24 hours initiates a dramatic change 
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in gene expression profile more similar to HSCs in later stages of culture (day 10) than 
freshly isolated cells [94]. Therefore, the aims of chapter 3 of this dissertation were to 
examine differential gene expression between truly quiescent (freshly isolated) and fully 
activated (14 days on plastic) HSCs. Several groups have performed mRNA microarray 
analyses comparing quiescent and activated phenotypes isolated from both in vitro and in 
vivo settings [199-200]; however, little is known about the daily genetic alterations that 
occur. To fully understand transdifferentiation, it is necessary to know the sequential 
activation of key genes, as well coordinate patterns of expression. Therefore, based on 
known gene expression profiles of quiescent and activated HSCs, several genes were 
selected to follow throughout transdifferentiation. Our study analyzed an array of 21 
genes over 10 consecutive days in culture to identify candidate signaling pathways and 
genes which peak early in expression to initiate and commit the HSC to 
activation/transdifferentiation.   
Using AMADA software, genotypic clustering was performed to profile genes 
that are modulated in quiescence, early and late activation, and pro-fibrotic conditions. 
Analyses demonstrated day Q was clearly divergent from all other days during 
transdifferentiation, while days 1-3 were significantly different from days 5-10.  Further, 
day 4 is genetically distinct from all other days in culture, suggesting this may be the 
commitment point to the activated phenotype.  Additionally, components of the IL-6 
JAK/STAT signaling pathway appeared to be pivotal in the first 72 hours of HSC 
transdifferentiation. Results also demonstrated chemical inhibition of the JAK/STAT 
signaling pathway blunted phenotypic changes seen during activation as indicated by 
retention of cytoplasmic projections and significantly decreased pro-fibrotic gene 
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expression. Overall, these data demonstrate shifting of genetic profiles during early 
activation results in differentiation into a unique phenotype rendering the cell sensitive to 
ligands that signal through JAK/STAT.  Since inhibition of the JAK/STAT signaling 
pathway impedes progression of HSC transdifferentiation/activation, this may serve as a 
potential therapeutic target to inhibit or slow development of hepatic fibrosis. While not 
directly confirmed in our experiments, several reports have shown AG490 (100 mol/L) 
significantly inhibits the activity of JAK2 with subsequent decreases in STAT3 
phosphorylation [266-268], confirming its use as an effective chemical inhibitor. 
However, as a tyrosine kinase inhibitor, it is possible that AG490 could potentially affect 
the activity of other similarly structured receptors. Therefore, future studies utilizing 
specific gene silencing molecules (small interfering RNA or short hairpin RNA) should 
be performed to confirm our findings. Uncovering the vital function of JAK/STAT in the 
transduction of signals necessary to initiate HSC transdifferentiation will undoubtedly 
expand the arsenal of pharmaceutical inhibitors used to treat fibrosis [94].  
In addition to JAK/STAT signaling, TGF is critical to both initiation and 
perpetuation phases of transdifferentiation. Post-liver injury both blood and tissue 
TGFlevels are elevated stimulating HSC transdifferentiatioin. Increased TGF 
stimulates expression of procollagen and other profibrogenic target genes [84, 226]. In 
addition to paracrine signals from damaged parenchymal cells, endogenous TGF 
synthesis is significantly increased as a result of transdifferentiation, underscoring the 
importance of this signaling network in the foundation and progression of hepatic 
fibrosis. Disruption of TGF signaling in activated HSCs both in vitro and in vivo 
markedly decreased fibrosis in experimental animal models [23, 31-32]. However, no 
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studies to date have examined global factors regulating TGF signaling in HSCs in 
efforts to design novel therapies against pro-fibrotic signaling. miRs act as key regulatory 
molecules in hepatic fibrosis controlling gene expression by binding to 3’UTRs of target 
genes inducing mRNA instability or translational repression [140]. miR-based regulation 
of genes controlling HSC transdifferentiation has been demonstrated, highlighting a 
novel area of therapeutic intervention [184]. Microarray analyses showed a significant 
down-regulation of miR 19b in activated compared to quiescent HSCs. In silico analyses 
predicts miR 19b binding to the 3’UTR of TGFRII, a component critical to successful 
signal transduction, which were validated by dual luciferase reporter assays. 
Overexpression of miR 19b in activated HSCs suppressed TGFRII expression with 
subsequent repression of SMAD3 and downstream target gene, type I collagen. In 
addition to suppression of pro-fibrotic signaling, marked reduction in HSC activation was 
also observed. miR 19b mimics induced significant reductions in activated morphology 
with corresponding decreases in SMA mRNA and protein. Additionally, forced miR 
19b expression decreased epigenetic regulator and suppressor of quiescence MeCP2 
accompanied by restoration of quiescent marker GFAP. In vivo studies confirmed 
decreased miR 19b expression in fibrotic liver tissue. More importantly, miR 19b 
expression was significantly down-regulated in tissue from human fibrotic patients, 
highlighting a new role of miR 19b as a novel fibrotic biomarker and possible 
therapeutic. Significantly decreased levels of miR 19b were detected in liver tissues from 
fibrotic patients with various underlying etiologies, indicating a highly conserved role of 
this miR in fibrogenesis.  
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As HCV represents the major cause of hepatic fibrosis on a global scale, it would 
be interesting to confirm the in vitro findings in HCV-infected HSCs utilizing a newly 
developed sub-genomic replicon system. Additionally, as rates of HCV recurrence post-
transplant remain high, identifying liver transplant recipients at greatest risk for rapid 
development of fibrosis from recurrent hepatitis C would target those recipients most 
urgently in need of antiviral therapy and defer treatment to those at less risk for disease 
progression. To this end, recent studies have shown inverse correlations between tissue 
and plasma miR levels [242-243]. In fact, miR 19b was up-regulated 4.3-fold in serum of 
individuals with cirrhotic livers compared to normal controls [244]. Therefore, examining 
expression levels of miR 19b in HCV transplant patients could lead to development of a 
reliable marker to identify rapid progressors of fibrosis.  
Modulation of miR 19b expression in fibrotic animal models is necessary to 
confirm the contributions of this specific miR in HSC-mediated fibrogenesis. While 
potential clearly exists for miR 19b as a serum biomarker of fibrosis, it is imperative that 
future studies examine other tissues and cell types for expression of this miR under 
normal and injured liver conditions to determine if the observed decreased in expression 
occurs on a global level.  
Resolution of hepatic fibrosis has been attributed to inhibition of HSC 
transdifferentiation, interruption of pro-fibrotic signaling, and induction of HSC 
apoptosis [49, 170, 269]. However, activated HSCs have been reported to demonstrate 
increased resistance to apoptosis due to increased bcl-2 expression [52]. Still, activated 
HSCs are capable of undergoing apoptosis in response to a variety of stimuli including 
gliotoxin, superoxide radicals, and tumor necrosis factor-related apoptosis-inducing 
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ligand (TRAIL) [169-170, 173, 254]. Previous studies demonstrated water movement 
during apoptosis occurs via AQPs [159-160, 162] , and inhibition of AQP-dependent 
water movement during the apoptotic volume decrease significantly slows apoptotic 
progression [160-161, 164]. In contrast to quiescent HSCs, activated cells were 
characterized by marked decreases in net AQP expression. Interestingly, while message 
was detected for 7 AQPs in quiescent HSCs, only 4 homologs were detected at the 
protein level. Future studies should examine the molecular mechanisms contributing to 
this discrepancy and determine the specific solute/s transported by each AQP within the 
HSC. Current literature has not indicated such a redundancy in AQP expression within 
other cell types; therefore, examination of specific cellular localization of each homolog 
would contribute to our overall understanding of which AQP/s may be critical for cellular 
functions.  Using osmotic challenge, in the absence and presence of a non-specific AQP 
channel blocker (HgCl2), rapid AQP-dependent water movement across the plasma 
membrane in quiescent HSCs was observed indicating the presence of functional AQP 
homologs within the plasma membrane. Conversely, activated HSCs failed to respond to 
osmotic challenge. Quiescent HSCs (4 hours), expressing multiple AQP homologs, were 
significantly more responsive to apoptotic stimulation versus activated HSCs. Finally, 
confirming in vitro studies, fluorescent immunohistochemistry showed strong 
colocalization between quiescent HSCs and AQPs 8 and 9, while α-SMA positive HSCs 
found in fibrotic liver tissue exhibited dramatically decreased AQP expression. These 
data demonstrate HSCs express AQPs and suggest regulation of AQP expression/function 
contributes to HSC susceptibility to apoptotic challenge. These data indicate it will be of 
considerable interest to study AQP expression and apoptosis in HSCs using animal 
 135
models of progressive liver injury in which the magnitude and duration of the hepatic 
insult can be manipulated. In doing so, direct or indirect modulation of AQP expression 
in HSCs may lead to the development of novel therapeutics for the treatment of hepatic 
fibrosis. 
 HSC transdifferentiation is highly complex with breadth and depth existing in 
pro-fibrotic signaling networks conferring phenotype-specific genetic reprogramming. 
This dissertation examined multiple points of the HSC transdifferentiation process to 
uncover novel molecular mechanisms regulating the pro-fibrotic condition that may be 
manipulated to create novel therapeutic strategies. Cumulatively these data show 
JAK/STAT signaling stimulates early HSC transdifferentiation, miR 19b regulates pro-
fibrotic TGF signaling which both establishes and perpetuates the activated phenotype, 
and finally, decreased AQP expression contributes to increased resistance to apoptotic 
stimuli observed in activated cells. All of the aforementioned discoveries represent novel 
avenues to be explored. 
 Pharmaceutical intervention and gene therapy while previously unsuccessful for 
the treatment of fibrosis remain under constant revision with a flux of new information 
and technology driven advances. Specifically, new miR-targeted drug Miravirsen 
(SPC3649), developed by Santaris Pharma, is in Phase II clinical trials for treatment of 
HCV via inhibition of miR 122 (ClinicalTrials.gov). Additionally, new adeno-associated 
virus (AAV) constructs are being used in rodent models and hold deeper clinical promise 
than previous clinical trials using adenovirus based gene therapy. AAV is currently in use 
for several clinical trials including Duchennes’ muscular dystrophy [270], Pompe 
Disease, and Parkinson’s disease (ClinicalTrials.gov). Site-specific integration in the 
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absence of deleterious immunogenic response makes AAV therapy an attractive option. 
Delivery of miR 19b via AAV may prove to be a powerful therapeutic strategy as 
delivery of miRs for treatment of hepatocellular carcinoma has been extremely effective 
and devoid of deleterious side-effects in rodent models [241, 271]. Additionally, AAV 
vectors delivering JAK2 genetic/chemical inhibitors, or constructs designed to 
overexpress AQPs also hold promise. However, these treatments to be successful, an 
HSC-specific marker should be identified to avoid damaging neighboring cells and 
possible systemic effects. Deep sequencing of each HSC genetic program may provide 
novel mRNAs/non-coding RNAs that could be used for direct targeting.   
In addition to therapies, it is important we improve our ability to predict disease 
progression and outcome. miR expression profiles have proven indicative of disease 
states in animal models of chronic liver disease and in patients with various underlying 
etiologies [175-176, 272-273]. miR 19b may prove to be a novel biomarker of hepatic 
fibrosis, and with new technological advances allowing measurement of miRs in serum, 
simple clinical testing and standard of care blood draws may facilitate non-invasive 
measurements of patient health status [274-275].  
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